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 The focus of this thesis is on detecting and quantifying drug-related risks faced 
by in-patients in Singapore, followed by assessing and managing these risks from the 
perspective of a pharmacist. Currently, there are no formal local studies that 
investigate specifically into drug related problems (DRPs) and adverse drug reactions 
(ADRs) to evaluate the situation and to implement strategies to minimize the 
occurrence of these problems. To address the aforementioned conditions, this thesis 
attempted to establish the current level of risk that the patients were exposed to in the 
healthcare environment, as well as to ascertain the contributory factors for the 
increased risk. This was followed by an attempt to evaluate the clinical and 
economical impact on increased and systematic involvement by pharmacists in 
reducing these risks. Thereafter, a quantitative tool in assessing ADR with the view 
that risk of DRPs, namely ADR could be greatly reduced with a better instrument in 
an improved healthcare environment. 
 
 This thesis found that the DRPs detected in in-patients were mainly avoidable. 
With this knowledge of a more exact representation of the situation locally, it would 
then be possible to develop and implement strategies which would help in detecting, 
assessing and managing the situation of DRPs. This finding led the next step of the 
thesis to a follow-up study which studies the impact of regular pharmacist’s 
participation in a physician-pharmacist review team. It was shown that with the 
presence of a pharmacist in a primary patient care review team, more DRPs (and even 
potential DRPs) were detected and were promptly averted. There was significant total 
drug cost savings during the study period (linearly projected as $42 000 annually) 
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when there was a pharmacist on board the review team. The cost-benefit ratio of such 
an arrangement was calculated to be 5.84. This positive ratio, on top of a net annual 
return of $42 000 in investing in a pharmacist to perform such monitoring tasks 
seemed to substantiate the cost-effectiveness for hospital administrators to endorse 
such pharmaceutical care services.  
 
 After evaluating the inclusion of a pharmacist into the regular ward round as a 
change in system to reduce clinical risk to the patients.  The next study performed was 
to evaluate whether the existing tools for assessing and ascertaining risk is suitable or 
sufficient for the pharmacists to carry out the task efficiently.  A thorough assessment 
of the available tools and the reality of readily available clinical data demonstrated the 
necessity to develop a simpler and user-friendlier tool to assist the pharmacists in the 
task.  In this thesis, a new quantitative ADR causality scale was developed. A severity 
assessment scale for comparing the intensities of the severity of various ADRs was 
also produced and incorporated with the abovementioned ADR scale. This 
amalgamation provides a novel combined ADR causality and severity scoring system 
which will serve to give more practical value to the results obtained compared to the 
individual causality and severity scores. This scoring system could be utilized to 
facilitate ADR signal generation for general drugs or for targeted drugs. Its 
quantitative nature can also help clinicians, investigators and the regulatory 
authorities in case management when they are faced with limited time and resources. 
This scoring system will also be a useful tool for pharmacists in patient care review 




 From the results obtained from these studies, it could be inferred that with a 
change in the workflow of the current healthcare system in Singapore and by 
equipping the pharmacists with user-friendlier tools (e.g. the algorithm developed in 
this thesis), it would be possible to allow the pharmacists to play a much bigger role 
in contributing to clinical risk management. 
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Introduction 
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1.1 Overview 
 Risk management in the pharmaceutical sense is a term used to describe the 
process of actively identifying, assessing, communicating and minimizing the risks 
which may arise from using a drug.1 Ideally, such processes which seek to establish 
and maintain a favorable benefit-risk balance in patients should take place at different 
stages of the life-cycle of a drug, from its development all the way to post-marketing 
surveillance of the drug used in the general population. Although drugs are meant to 
provide patients with relatively predictable beneficial effects, unfortunately they also 
have the potential to cause unexpected and unwanted effects. These unwanted effects 
may range from minor side effects to major debilitating effects, or in the worse case 
scenario, fatal consequence.  
 
 The term drug-related problems (DRPs) is used to describe these 
consequences which are different from the intended pharmacotherapeutic effect of the 
drugs involved.2 However, this is only a brief and simplistic summary of what DRPs 
encompass. According to Strand et al.,3 DRPs would include the following eight 
broad categories - adverse drug reactions (ADRs); untreated indication; drug use 
without indication; improper drug selection; using subtherapeutic dose of drug; 
excessive dose of a correct drug; drug interaction; and failure to receive drug.  
 
 The focus of this thesis is on detecting and quantifying these drug-related risks 
faced by in-patients in Singapore, followed by assessing these risks and managing 
them from the perspective of a pharmacist. In this chapter, an introduction to DRPs 
and ADRs would be provided (Section 1.2), followed by a brief review of work done 
to date for the management of DRPs and ADRs (Sections 1.3 and 1.4 respectively). 
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Thereafter, the rationale to assess the DRP and ADR situation in Singapore would be 
discussed (Section 1.5). With this in place, a list of research motivations is then 
generated (Section 1.6). These questions will be examined in the subsequent chapters 
with each chapter detailing the methodology, results and discussion of the individual 
studies embarked upon to answer each issue with the hope that the summation of the 
study results would shed some lights as how to minimize and manage drug-related 
risks from the perspective of a pharmacist.  
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1.2 Introduction to Drug-Related Problems (DRPs) and Adverse 
Drug Reactions (ADRs) 
1.2.1 Drug-related problems 
 As briefly mentioned earlier, DRPs which include adverse drug reactions 
(ADRs), unnecessary drug therapy, inappropriate choice of drugs, and untreated 
conditions, have been shown to prevail in hospitalized patients, with a reported 
incidence rate as high as 25%.4, 5 Due to their association with increased rates of 
morbidity and mortality, DRPs continue to be a major problem faced by healthcare 
institutions worldwide.2, 6-8 Inappropriate prescribing of medications, ADRs and drug 
interactions may cause increased morbidity and mortality, and treating these 
iatrogenic complications further burdens the health care system.6 This is in view of 
patients requiring more nursing care, more attention by the attending physician, and 
possibly additional drugs to treat the resulting adverse reaction or interaction.7 All 
these inevitably lower the quality of life of the patient. Moreover, the extent and cost 
of drug related morbidity and mortality are of great importance to health care 
practitioners, administrators, patients and society as a whole.2 
 
 Many factors can contribute to the high prevalence rate of DRPs, but among 
these factors, polypharmacy and older age have often been identified as important risk 
factors.4, 9, 10 
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1.2.1.1 Causes of the various DRPs 
As stated earlier in this chapter, there are 8 different types of DRPs. These are their 
associated causes, adapted for use in this dissertation11: 
1. Adverse drug reaction 
a. The drug was administered too rapidly for this patient 
b. The patient is having an allergic reaction to this medication 
c. The patient has identified risk factors that make the administered drug 
too dangerous to be used 
d. The patient has experienced an idiosyncratic reaction to the 
administered drug 
2. Untreated indication 
a. The patient has a new medical condition requiring initiation of new 
drug therapy but not receiving the drug 
b. The patient has a chronic disorder requiring continuation of drug 
therapy but is not receiving it 
c. The patient has a medical condition that requires combination 
pharmacotherapy to attain synergism/potentiation of effects 
d. The patient is at risk to develop a new medical condition preventable 
by the use of prophylactic drug therapy and/or pre-medication 
3. Drug use without indication 
a. The patient is taking a medication for which there is no valid medical 
indication at this time 
b. The patient accidentally or intentionally ingested a toxic amount of a 
drug or chemical, resulting in the present illness or condition 
c. The patient’s medical condition is better treated with non-drug therapy 
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d. The patient is taking multiple drugs for a condition for which only 
single-drug therapy is indicated 
e. The patient is taking drug therapy to treat an avoidable adverse 
reaction associated with another medication 
4. Improper drug selection 
a. The patient has a medical problem for which the administered drug is 
not effective 
b. Patient is allergic to the administered medication 
c. Patient is receiving a drug that is not the most effective for the 
indication being treated 
d. The patient has risk factors that contraindicate the use of the 
administered drug 
e. The patient is receiving a drug that is effective but not the least costly 
f. The patient is receiving a drug that is effective but not the most safe 
g. The patient has an infection involving organisms that are resistant to 
the administered drug 
h. The patient has become refractory to the present drug therapy 
i. The patient is receiving an unnecessary combination product when a 
single drug would be appropriate 
5. Subtherapeutic dose 
a. The dosage used is too low to produce the desired response for this 
patient 
b. The patient’s serum drug concentrations are below the desired 
therapeutic range 
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c. Drug, dose, route, or formulation conversions were inadequate for the 
patient 
d. Dose and interval flexibility (insulin sliding scales, “as needed” 
analgesics) were inadequate for the patient 
6. Excessive dose 
a. Dosage is too high for the patient 
b. The patient’s serum drug concentrations are above the desired 
therapeutic range 
c. The patient’s drug dose was escalated too rapidly 
d. The patient has accumulated drug from chronic administration 
e. Drug, dose, route, formulation conversions were inappropriate for the 
patient 
f. Dose and interval flexibility (insulin sliding scales, “as needed” 
analgesics) were inappropriate for the patient 
7. Drug interaction 
a. The bioavailability of the drug is altered due to an interaction with 
another drug or food the patient is taking 
b. The effect of the drug has been altered due to enzyme 
inhibition/induction from another drug the patient is taking 
c. The effect of the drug has been altered due to displacement from 
binding sites by another drug the patient is taking 
8. Failure to receive drug 
a. The patient did not receive the appropriate drug regimen because a 
medication error (including prescribing, dispensing, administration or 
monitoring) was made 
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b. The patient did not comply (adherence) with the recommended 
directions for using the medication 
c. The patient did not take the drug as directed owing to the high cost of 
the product 
d. The patient did not take the drug as directed because of lack of 
understanding of the directions 
e. The patient did not take the drug as directed because it would not be 
consistent with the patient’s health beliefs 
 
1.2.1.2 Influence of polypharmacy on DRP 
 Polypharmacy is defined as the use of multiple medications by a single patient 
and is commonly observed among geriatric patients.4 The use of multiple medications 
has been shown to predispose patients to ADRs,10, 12-15 drug-drug interactions,4, 16, 17 
and medication non-compliance,18-20 particularly in the geriatric population. 
 
 Besides the undesirable clinical consequences for the patients, DRPs (mostly 
ADRs) also pose a significant financial burden to the healthcare system.6 In a US 
study performed in 1992–1994, the estimated cost of treating reported adverse drug 
events among in-patients was US$1.5 million per year at a university-affiliated 
hospital.21 Another more recent French study conducted in 1996–1997 showed the 
annual cost of drug-related hospital admission to a university hospital as €3.85 million 
per year.22 Thus, reducing the use of unnecessary medicines and avoiding 
polypharmacy would be beneficial in aiding the reduction of healthcare cost beyond 
the confine of reduction in drug costs alone. 
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1.2.1.3 Influence of age on DRP 
 Amongst all the risk factors, advanced age has been associated with 
substantial increased risk of acquiring ADR.23 A sevenfold increase in occurrence of 
ADRs from 3% to 21% has been shown to occur between patients aged 20–30 years 
and patients aged 60–70 years.24 However, other researchers had argued that this 
propensity of older patients experiencing ADR was not well substantiated by 
epidemiological data.13 Furthermore, the failure to control for important age-related 
covariates, e.g., clinical status of the patient, had also been cited as a limitation to the 
interpretation of many study results.25 Some researchers had proposed that 
inappropriate medication in the elderly might pose a higher risk for acquiring ADR 
than advanced age as a sole risk factor.26 Up to now, the issue of whether 
inappropriate drug use or advanced age should be considered the more important risk 
factor for causing DRPs remains unresolved. The resolution of this issue is of great 
relevance to the practice of clinical medicine, as it would allow physicians and 
pharmacists to focus more attention on patients with the “true” risk factors. 
 
1.2.2 Adverse drug reactions 
 Adverse Drug Reaction (ADR) is recognized as a major contributor in 
iatrogenic illness. ADRs are known to complicate management of existing disease, 
and affect patients’ quality of life.27 ADRs may also result in delay in cure of the 
original disease as well as inappropriate treatment of unrecognized drug-induced 
problems.2, 8, 10, 27, 28 Epidemiological studies have indicated that the range of reported 
ADRs that occur during a hospitalization episode could vary from 1.5 to 43.5%.29 The 
use of different definitions of ADRs coupled with the presence of different ADR 
reporting systems and the amount of emphasis placed on ADR reporting would all 
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have contributed to this wide range. Nevertheless, the general consensus that ADR is 
a major problem encountered in clinical medicine is unchallenged. 
 
 Besides increased morbidity and mortality caused, the economic consequences 
of ADRs are often serious.30 Data from both USA and Europe showed ADRs could 
impose a heavy financial burden on the healthcare system.31-33 For instance, an 
American study estimated the average cost of treating reported adverse drug events 
occurring among in-patients amounted to US$1.5 million per year at an university-
affiliated hospital,21 while a study in a general hospital in France showed an estimated 
annual cost of treating adverse drug reaction to be €161 837.31 
 
 Hence, ADRs as one of the most important categories of iatrogenic illness, 
have significant medico-legal and economic ramifications.34 This has brought on 
ADR reporting as a major initiative in contributing to maintaining drug safety at both 
the institutional and national level in many healthcare systems. The reporting of 
ADRs is of great importance for issuing alerts to reduce or prevent similar incidences. 
At the same time, consolidating all ADRs reports can generate signals which alert 
regulatory authorities to perform risk-benefit assessments for the drugs involved with 
the aim of safeguarding public health. In Singapore, data from the Pharmacovigilance 
Unit, at Centre for Drug Administration (CDA) (which is responsible for collating all 
ADR reports for the nation) showed a near 3-fold increase of ADR reporting from 391 
cases in the year 2000 to 1103 cases in the year 2003 (Figure 1.1). This increase 
would substantially be due to a heightened ADR awareness as a result of the many 
promotion campaigns conducted by the Health Sciences Authority over the years and 
hence causing an increase in voluntary reporting. Nevertheless, the increase in ADR 
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reporting does highlight the need for a more effective way to assess ADR causality. 
The faster and more accurately a signal is identified, the sooner the appropriate 
remedial actions can be implemented. From the perspective of the regulatory 
authorities, a rapid and reproducible ADR identification will also translate to faster 
dissemination of alerts. This is especially important for serious ADRs. 
 


























 In many jurisdictions, pharmacovigilance is under the purview of the drug 
regulatory authorities.35 Spontaneous reporting of suspected adverse reactions to 
drugs is currently the norm and backbone of pharmacovigilance internationally.35 
However, spontaneous reporting often produces only circumstantial evidence with 
uncertainties pertaining to the causal involvement of the drugs.36 Therefore, further 
assessments are needed to confirm causality, identify risk factors, and also measure 
the occurrence frequency of ADRs. Besides causality, which is the likelihood of the 
suspected drug causing the ADR, another important criterion for assessing ADRs will 
be the severity. The ascertainment of these two criteria, will aid the regulatory 
authorities in evaluating the risks associated with the signals generated by ADR 
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reports, and making decisions on the necessary and most appropriate remedial 
measures. These may include the re-evaluation of the drug involved for the suitability 
of its approved indications, a requirement for additional special cautionary labels or 
changes in package inserts, or withdrawal of the drug. For the health-care 
professionals, this information can assist in the judgment of the risk-benefit in using 
the drugs to treat a condition. 
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1.3 Work done to date for the management of Drug-Related 
Problems (DRPs) 
 Despite the efforts of healthcare professionals in reducing DRPs, it is 
considered that a large proportion of these DRPs are preventable.8 Although the 
influence of age and gender are inherent in DRPs and cannot be changed, the 
geriatrics and female patients will have to be monitored more closely to prevent DRPs 
from occurring or to detect the first signs of possible DRPs and manage them 
accordingly. Where polypharmacy is concerned, proper management of patients’ drug 
therapy will help in risk minimization. 
 
 In the last decade, pharmacists have contributed to improvements in the areas 
of drug therapy and patient safety. There has been a paradigm shift from their 
traditional roles of distribution and dispensing of medications to the active 
involvement in the direct provision of pharmaceutical care.37-47 
 
 Pharmaceutical care implies communicating and reaching a consensus with 
physician regarding pharmacotherapy.39 The pharmacists will be more involved in 
identification and solutions of problems related to drugs, and to prevent drug-related 
problems from occurring. Some of the interventions carried out by the pharmacists 
include advising of appropriate surgical antibiotic prophylaxis, performing 
pharmacokinetic monitoring, initiation and discontinuation of drug therapy, 
suggesting of alternative pharmacotherapy, as well as influencing the modification of 
drugs’ dose, frequency and route of administration.37, 39 Such pharmacist interventions 
strive to achieve a rationale and optimal use of drugs. For this to take place effectively, 
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pharmacists have to participate actively and coordinate with other health-care 
professionals in multidisciplinary care.37, 39-44 Going on ward rounds as a member of 
the patient care team will allow the pharmacists to provide such services most 
efficiently.40 The pharmacists will be able to intervene immediately when the need 
arises, rather than to spend time checking and correcting prescription orders after they 
have been sent to the pharmacy.  
 
 Such pharmaceutical care provision has been shown to reduce the number of 
adverse drug events and the length of hospital stay.48 Other than signifying a lower 
rate of DRPs, all these reduction of adverse events and length of stay also translate to 
cost savings and cost avoidance in the medical institutions.39, 41, 44 In 1997, Mutnick et 
al.44 presented the results of 4648 interventions carried out by 50 pharmacists during a 
9 months study at a 849-bed institution. These interventions were based on the 
pharmacist’s evaluation of the patient, the condition involved, and the appropriateness 
of the drug therapy prescribed. Of these interventions, 87% were accepted by the 
medical staff, and these accepted interventions represent a net therapy cost saving of 
US$487,833, as well as a cost avoidance of US$158,563 achieved by preventing a 
potential net 371.9 additional hospital days. In a more recent study published in 2003, 
Galindo et al.39 analyzed 3136 pharmacists’ interventions that were collected 
prospectively for 6 months in a 330-bed acute hospital. The medical practitioners 
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1.4 Work done to date for the management of ADRs 
 To date, there are immense efforts in many countries to detect ADRs via 
various methods with the intention of distinguishing the real ADRs and incorporating 
safety nets to either prevent similar ADRs from occurring or to allow rapid 
identification of analogous ADRs. Such detections take place on different scales from 
within the institution,49-51 to within the country,52 and even across different countries 
in the world like what FDA and WHO-UMC are doing.53, 54 
  
 Within medical institutions, efforts to detect ADRs are usually through their 
own computerized systems. All health-care professionals (physicians, nurses, 
pharmacists) are encouraged to report ADRs detected to the hospital’s pharmacy 
department.49, 51, 55 Such spontaneous reports are captured in databases. In most cases, 
pharmacists or the hospital ADR review committees will evaluate the recorded ADRs 
to pick out trends in the reported ADRs. The information is then circulated to the 
prescribers with the intention of reducing future adverse reactions. When ADR 
management is done on a larger scale, it is too time consuming to have medical 
personnel going through each and every report to detect if the ADR is genuine and if 
an alert for a particular ADR needs to be disseminated. Hence, more comprehensive 
databases which are programmed to pick out ADR alert signals from data mining of 
huge number of reports are used.53, 56, 57 These types of monitoring systems are 
generally organized at national level. 
 
 Where individual general practitioners are concerned, the relatively small 
number of cases that the doctor encounter would make the chance of arriving at 
worthwhile results too small.30 Moreover, in cases of clinical practice where ADR 
 
Chapter 1: Introduction 16
causality need to be determined immediately, or in organizations whereby computer 
data system is not as comprehensive, the traditional use of ADR algorithms58-62 to 
identify causality of suspected drug still remains the most ideal. The presence of 
operational identification of ADRs incorporates an estimate of the certainty of the link 
between the untoward clinical event and the suspect drug. ADR algorithms are able to 
increase inter-rater agreement when assessing ADR causality,58, 60 and also brings 
about better intra-rater reliability when assessing the ADR cases.58 
 
 Since the reason for going through the effort of detecting ADRs is to allow 
medical professionals to make the right diagnosis and to ensure safe usage of the 
drugs, it is important that information of established ADRs are passed on to the health 
care professionals as soon as feasible.63 Hence, once these ADRs are detected, 
assessed for their causality and the causative drugs established, the alerts will be 
circulated in publications either within the institution or at national level to health care 
professionals. If the ADRs are considered to be of serious nature, there will even be 
alerts at international level. Depending on the level of seriousness and severity of 
these ADRs, regulatory bodies will decide whether to allow the continued use of these 
drugs. At the same time, the respective drug companies will have to evaluate if a 
recall for the offending drug is necessitated.  
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1.5 Why is there a need to assess DRPs and ADRs situation in 
Singapore? 
 As mentioned earlier in this chapter, to carry out risk management, there has 
to be risk identification, assessment, communication and minimizing the risks. So far, 
the published papers retrieved from the literature search on the topics of DRPs and 
ADRs are reports of studies carried out in other countries. There are no formal local 
studies that examine DRPs and ADRs to evaluate the situation and to implement 
strategies to minimize the occurrence of these problems. Although overseas studies 
would be useful to a certain extent, they may not be truly representative of local 
situation. Henceforth, the motivation for this study comes from wanting to identify 
and assess the most exact state of DRPs and ADRs in Singapore, as well as the risk 
factors faced locally that contribute to these problems. The hypothesis is that the 
situation here is very much similar to those in other developed countries. Once a more 
exact representation of the situation here is established and evaluated via such reviews, 
it will be possible to develop and implement strategies which will help improve the 
situation of DRPs locally. 
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1.6 Research motivations 
 In the current project, it is intended to adapt from the broad framework of risk 
management. The project will target its principle for detecting, assessing, and 
managing risks that occur during drug therapy. 
 
 There are a few research questions that the current thesis sets out to answer: 
1. What is the current DRP situation in Singapore? 
a. Since DRPs have been shown to prevail in hospitalized patients, with 
polypharmacy and increasing age identified as two important risk 
factors,10, 14, 15, 23, 24 the study would aim to find out what is the 
incidence of DRPs-associated hospital admission, and its correlation to 
polypharmacy and age (see Chapter 2). This will be a baseline study 
for analyzing if the incidence of drug therapy related admission to 
hospital in Singapore will be comparable to that occurring in other 
developed countries as reported above. In addition, the verdict of 
whether the DRPs are avoidable will provide a basis to derive suitable 
strategies to lower the incidence of these drug therapy related 
admissions. 
b. After establishing the incidence and type of DRPs that are prevalent 
during hospital admission, the thesis will examine the occurrence of 
DRPs amongst hospitalized patients on polypharmacy to complete the 
picture (see Chapter 3). When at that, other than wanting to verify the 
association of advanced age with developing ADRs in in-patient, the 
study also seeks to confirm the correlation between the female gender 
and occurrence of ADRs. This phenomenon has been reported in 
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overseas studies28, 64, 65 and unless its incidence is established in 
Singapore, it will be difficult to substantiate the need to put forth the 
female gender as a risk factor for developing DRPs and ADRs. It is 
with the presence of a lucid guideline of the risk factors present that 
effective management measures can be implemented. The search for 
these risk factors will be the main intent. 
2. Will the current system in the hospital benefit from the presence of 
physician-pharmacist review teams? Will DRPs and medication costs be 
reduced as a result of the presence of such a team? 
a. Having targeted to detect the risk factors involved in DRPs, the focus 
will now be to find out how pharmacists can make an impact in trying 
to reduce the occurrence of these DRPs. There is already an emerging 
trend in Singapore whereby hospital pharmacists are shifting towards a 
clinical role in improving the quality of medical care for patients. 
However, the prevalence of a low pharmacist-to-patient ratio coupled 
with the fact that pharmacist are still not relieved of the role of 
medications distribution and dispensing makes it difficult for a 
pharmacist to go on regular ward rounds as part of a primary patient 
care team. Here, the impact of pharmacists’ participation in physician-
pharmacist review teams will be studied. The research question would 
be to evaluate if such review teams can actually help in the detection of 
DRPs at its early stage and whether efforts can be implemented to 
minimize these DRPs or even eradicate them. If these potential DRPs 
can be intervened successfully, then the next step would be to verify if 
there is any reduction in pharmacy costs and decrease in length of stay 
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of patients when there is such active participation of pharmacists in 
doctors’ ward rounds (see Chapter 4). Evaluating such potential cost-
savings measures may also help to justify the cost-effectiveness for the 
hospital to endorse such services. Such studies were done in abundance 
elsewhere39, 41, 44, 48 and without initiating this study, there will be no 
local data to justify the cost-effectiveness for the hospital to endorse 
such services and to allocate resources of them. 
3. Can the inadequacies present in some currently available ADR algorithms 
be improved upon? How can an ADR algorithm be further harnessed and 
developed into a functional and user-friendly tool in detecting and 
assessing ADRs? 
a. ADR is one big component of DRPs. In order to carry out 
comprehensive evaluation of DRPs, it is essential to have a good 
method of detecting and assessing ADRs as well. Currently, ADRs 
reporting within hospitals and even at national level are mostly done 
via spontaneous reporting. However, this is not the ideal method as it 
often produces only circumstantial evidence. A better method of 
accurately detecting ADR will be via causality algorithms.66 These 
algorithms are preferred over clinical judgment for assigning ADR 
causalities because of their systematic approach in information 
acquisition, and thus help to improve the reliability of the 
assessments.36, 58 However, due to the structure or data requirement of 
several commonly used algorithms, the problem of uncertainties 
pertaining to the causal involvement of the suspected drugs may 
remain unresolved. Therefore, the study question is to develop an 
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improved algorithm that can provide more consistent drug risk 
probability using information that are easily available to the physician 
or regulatory personnel (see Chapter 5). 
b. For almost all existing ADR algorithms, each criterion in the 
algorithms was arbitrarily assigned weights based on its perceived 
importance. Such qualitative system is unable to determine the 
probability of the ADR causality based on the results obtained. If there 
is a probability scoring system, a quantitative likelihood of the ADR 
being caused by the suspected drug can be determined using such an 
algorithm. Noting the limitation of a qualitative approach to the 
existing ADR causality algorithms, the researcher would take up the 
challenge to develop a quantitative causality scoring system (see 
Chapter 6).  
For this quantitative scoring system, the power of genetic algorithm is 
harnessed. Genetic algorithm is a heuristic artificial intelligence 
algorithm that mimics some of the processes observed in natural 
evolution.67 It is useful for the optimization of problems that require 
high demands on computational resources. Examples of such problems 
where genetic algorithms have been used are multi-disorder 
diagnosis,68 determination of treatment doses for radiation therapy69, 70 
and patient scheduling.71 With the development of a quantitative 
scoring system, the final score of the ADR algorithm can also be used 
as a measure of the probability of ADR causality. 
c. However, the determination of ADR causality without establishing its 
severity may be reckoned as incomplete (see Chapter 7). With the 
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presence of both ADR causality and severity, it will be easier for 
health professionals to make decision on the management of ADR, as 
well as to decide on the benefit-risk ratio regarding further use of the 
drug involved. For that reason, the researcher sets to develop an 
assessment scale to determine the severity of ADRs (see Chapter 7). 
Following that, this severity assessment would be integrated with the 
ADR causality probability scale to give an overall score. To further 
improve the functionality of this score, they are classified into various 
alert zones. These zones will now provide users in settling on the most 
appropriate course of action to be taken following the particular ADR 
detection. 
 
 In each of the following chapters of the thesis, details of the studies which 
resulted from these motivations will be described. 
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2.1 Introduction 
 Publications have shown DRPs to be a common reason for hospital 
admission.64, 72 Admittedly, many factors contribute to DRPs in patient management. 
However, among these factors, polypharmacy and older age have often been 
identified as important risk factors for patients suffering from DRPs.4, 9, 10 
 
 Polypharmacy is defined as the use of multiple medications by a single 
patient,4 and this usually results from the prescription, administration, or use of more 
medications than is clinically indicated in a given patient.9 This use of multiple 
medications can easily predispose patients to drug-related problems (DRPs) like 
adverse drug reactions (ADRs), drug-drug interactions, and non-compliance.4 
 
 ADRs incidences have been consistently shown to increase with the number of 
drugs taken.4, 10 It has been shown that significantly more patients for whom four or 
more drugs had been prescribed were admitted to hospitals because of ADRs than 
patients receiving up to three drugs (11.1% vs. 3.6%).64 
  
 Besides higher risk of experiencing ADRs, the use of multiple medications 
also makes compliance with medication regimens more difficult.4 This is evident in a 
study which showed that medication errors, largely made up of non-compliance, 
increased from about 15% when only one drug was prescribed to 25% when two or 
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 Other than polypharmacy, advancing age has been shown to contribute to the 
substantial increase in risk of acquiring ADR, and hence increased risk of DRP-
related hospital admission as well.10 This is supported by data which showed a 
sevenfold increase in occurrence of ADRs from 3% in patients aged 20 to 30 years to 
21% in patients aged 60 to 70 years.24 However, this propensity of more older patients 
getting ADR may be due to higher risk of inappropriate medication rather than just 
advancing age as a sole risk factor.13, 26, 74 
 
 Hence, it can be seen from the above that polypharmacy can have adverse 
clinical consequences on the patients. In addition, the strain on health care cost is also 
substantial.75 Nevertheless, although DRP-related hospital admission has been 
recognized as a healthcare problem, there has not been any formal research done in 
Singapore to study it systematically to date. As such, the correlations between DRPs 
with polypharmacy and age of patients have also not been examined and evaluated. 
 
 The current study intends to estimate the incidence of drug related admission 
to an acute care hospital in Singapore, and to evaluate its correlation to polypharmacy 
and age of the patients involved. 
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2.2 Method 
 A retrospective, cross-sectional study was carried out at Alexandra Hospital, a 
404-bed acute care hospital in Singapore. In-patient case-notes and medication 
records were used for data collection. The patients were included in the study if they 
were in-patients on the last two Thursdays of November and December 2000, and had 
satisfied the criterion of being on polypharmacy. 
 
 In the study, polypharmacy was defined as the consumption of 5 or more 
medications. Different strengths of the same drug were counted as one item. However, 
formulations of the one drug that require different routes of administration were 
regarded as separate items. Combination drugs, that are drugs with more than one 
active ingredient in it, were regarded as a single item. 
 
 Each patient was characterized as having or not having a DRP on admission. 
Only definite cases of admission related to drug therapy were distinguished as having 
a DRP. If there was any uncertainty because of lack of supporting documents, then the 
case was classified as not having a DRP. Documentation by the admitting doctor was 
used to check for problems like non-compliance and lack of required drug therapy. 
Patients who required modifications to their drug therapy as a result of a newly 
diagnosed medical condition or worsening of an existing medical condition were not 
characterized as having a DRP on admission. 
 
 Definitions from Hallas et al. was used to evaluate the identified DRPs 
on/coincidental to admission for their contribution to hospital admission and their 
avoidability.76 DRPs were classified as dominant reasons for hospitalization if they 
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were the main reason for admission. If there were other factors present which 
contributed to admission, then the DRP was classified as partly contributing. 
 
 The DRPs were deemed as avoidable if (i) they were caused by drug 
treatments which were obviously inappropriate or contraindicated; (ii) no measures 
were taken to counteract known adverse effects of the drug (e.g. extrapyramidal side 
effects of anti-psychotic drugs); (iii) patients were not compliant or were 
insufficiently educated about their medication. The DRP was classified as possibly 
avoidable if the patient’s disease state was considered to be potentially changing, 
thereby resulting in the need for altered drug therapy. Unavoidable DRPs would be 
those that were unpredictable.  
 
 The main investigator (YK) was involved in checking for the presence of 
DRPs and the subsequent characterisation of these DRPs. Any need for confirmation 
of decisions was resolved with the other investigators. 
 
 For data analysis, Chi-square test was employed to test for significant 
differences between the age of patients and their risk of getting DRPs. This test was 
also used to compare the risk of DRPs between patients on minor (5–9 drugs) and 
major polypharmacy (10 and more drugs). The a priori level of significance for all 
comparisons was p<0.05. 
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2.3 Results 
 There were 640 in-patients during the study period. Of these, 347 patients 
(54.2%) satisfied the criterion of being on polypharmacy. Their age ranged from 16 – 
97 years old (mean ± SD: 66 ± 18 years), and 43% of the study subjects were female. 
The number of medications per patients ranged from 5 to 14 (mean ± SD: 7.4 ± 2.1). 
Geriatric patients (that is patients over the age of 65) made up 58.2% of our study 
population. 
 
 There were 32 cases (10.8% of study population) of DRPs which resulted in or 
coincidental to admission. In 71.9% of these cases, DRPs were the dominant reasons 
for hospital admission, and contributing factors for the reminder. Based on the criteria 
by Hallas et al.,76 these DRPs were all avoidable and can be broadly classified into 
non-compliance (28.1%), adverse drug reactions (25%), require synergistic therapy 
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 For the 10 patients who required additional therapy, the existing medical 
conditions of nine of them may have been better controlled if synergistic drugs were 
added onto their current medication. The tenth patient was admitted as a result of 
syncope secondary to chronic anemia which was not treated with medication. Of the 
non-compliant patients, one of them had poor inhaler technique resulting in the 
exacerbation of his asthma problem. The remaining 8 patients were not compliant 
with their medication regime. 
 
 Among these DRPs, 52% were found in elderly patients (greater than 65 years 
old). However, statistical analysis showed that when corrected for the number of 
drugs used by the patients, the geriatrics did not appear to have a higher risk of 
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 Further analysis showed that there is a higher trend of DRP-related admission 
in patients on major polypharmacy as compared to those on minor polypharmacy 
(12.1% vs. 8.7%). In spite of this trend, there was no statistically significant 
difference between these 2 groups (p = 0.454). 
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2.4 Discussion 
 From the study results, 10.8% of the study population had DRPs which 
resulted in, or were detected on admission. This figure is lower than the 41% 
previously reported in Canada.77 However, in the Canadian study, DRPs were 
reported for all elderly patients aged 65 and above, and the number of medications per 
patient ranged from 0 to 17 (average 5.7). In the present study, only patients with 5 
drugs or more were recruited. Hence, DRPs present in patients consuming less than 5 
drugs may have been missed. Moreover, the incidence of 10.8% was likely to be an 
underestimate due to the lack of comprehensive charting of medical and medication 
history upon patient admission. 
 
 Due to the retrospective nature of the study design, incomplete charting of 
history was a major limitation in our study. It hindered our ability to judge if a fall 
experienced by a patient was due to an accident, secondary to a medical condition, or 
secondary to an ADR. Moreover, information regarding chronic disease states, drug 
prescribing and compliance was not routinely gathered from the patient or recorded 
by the admitting doctor. Hence, the ability of the present study in identification of 
inappropriate drug therapy, lack of therapy and non-compliance was limited. This 
may further contribute to relatively low cases of admission related to drug therapy. 
Nevertheless, even an incidence rate of 10% for patients on polypharmacy to have 
DRP-associated hospital admission would be a case of concern for any health care 
system. 
 
 Considering the major causes of drug-related hospital admissions, non-
compliance was the most common cause of DRP contributing to 28% of such hospital 
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admission. Eight patients were either non-compliant to their medications or diet, and 
one patient was not using his metered-dose inhaler properly. This would not be 
surprising as non-compliance had been strongly correlated with the number of 
medications given.73 It had been reported as the main reason for most out-patient 
treatment failure, and cause of serious medical complications.73  
 
 Following non-compliance, adverse drug reactions also played an important 
role as one of the causes of drug-related hospital admissions (25%) in the current 
study. All the identified ADRs were found to be avoidable if the patients were 
monitored closely to ensure they were getting the optimum dosage of medication 
based on the status of their conditions, and if plasma drug concentrations were 
monitored. Thus, this is an area which needs to be investigated as ADRs are known to 
complicate existing disease, affect quality of life and may delay cure of the original 
disease.10 Furthermore, ADRs may result in inappropriate treatment of unrecognized 
drug-induced problems. 
 
 Although the study results did not demonstrate any statistical significant 
difference between DRP-associated hospital admission between geriatrics and 
younger patients, the clinical importance of higher trend observed in geriatric patients 
may not be totally discounted. This could probably be due to the small sample size of 
the current study. 
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2.5 Conclusions 
 In conclusion, this baseline study suggests that the incidence of drug therapy 
related admission to hospital in Singapore would be comparable to that occurring in 
other developed countries. Of the major causes of drug-related hospital admissions, 
non-compliance was the most common cause of DRP, followed by ADRs. All the 
identified ADRs were found to be avoidable if the patients were monitored closely. 
This finding that the DRPs were mainly avoidable provides a basis to derive suitable 
strategies to lower the incidence of drug therapy related hospital admission.  
 
 Although the study results did not demonstrate any statistically significant 
difference in geriatric patients having higher DRP-associated hospital admission 
compared with younger patients, probably due to the small sample size of this current 
study, there is indeed a clinical importance of higher trend observed in geriatric 
patients. Effective management of medications taken by patients with special 
emphasis on the geriatrics should be incorporated into our future efforts. 
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3.1 Introduction 
 Amongst the potential contributing factors of DRPs, the association between 
polypharmacy and the incidence of ADRs has been most widely studied and 
documented. Incidences of ADR have been consistently shown to increase in an 
exponential rather than a linear manner with the number of drugs taken.10, 78-80 
Furthermore, it was reported in another study that hospitalized patients who 
experienced an adverse reaction took twice as many drugs (12.5 vs. 6.3 drugs) as 
patients without ADRs.78 
  
 Besides the number of drugs prescribed, many studies have shown that a large 
number of emergency room visits and hospital admissions amongst older people 
could be attributed to iatrogenic syndromes associated with polypharmacy.81-85 Hence, 
polypharmacy plus old age could be considered a potent combination for ADRs to 
take place. The high risk of developing ADRs in patients with both risk factors was 
demonstrated when 35% of a study population of 167 older patients prescribed 
polypharmacy (taking 5 or more drugs) experienced a confirmed adverse drug event 
over a one-year period.81 
 
 Another interesting observation about the studies relating to DRPs is that there 
exists little data on comprehensive DRPs among hospitalized patients. So far, most 
studies published had addressed either the problem of drug-related admissions to 
hospitals,64, 65, 77, 86-88 or focused only on ADRs among hospitalized patients.75, 78, 89 A 
more comprehensive study of DRPs in hospitalized patients would provide valuable 
insights for the healthcare professionals trying to reduce the incidence of DRPs. 
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 Finally, another issue that is pertinent to healthcare delivery and risk 
management is the impact of the numerous studies of DRPs on clinical practice. As 
most of the studies were performed between 10 to 20 years ago,64, 65, 75, 77, 78, 86-89 it is 
unclear whether the results and lessons learnt from these studies have any influence 
on changing clinical practices. An assessment of the current situation would assist the 
healthcare providers in optimizing intervention strategies according to needs and 
available resources. 
 
 In the current study, the researcher attempted to evaluate some of the 
aforementioned issues. As polypharmacy has been established to be associated with 
the increased occurrence of DRPs,10, 18, 26, 87, 90 the main objectives were to investigate 
the occurrence of all DRPs (at admissions and while hospitalized) among hospitalized 
patients prescribed polypharmacy and evaluate the association of two risk factors, 
namely advanced age and female gender, with DRPs, especially ADRs.  
 
 Since advanced age had always been associated with higher incidence of 
DRPs,15, 72, 78, 91 the researcher wanted to see if this trend could be confirmed or 
supported by local data. Also, female patients, being generally lighter in weight and 
smaller in build than their male counterparts (especially among Asians) but usually 
receiving the same drug doses, had been demonstrated to be more prone to ADRs in 
some studies.28, 64, 65 This is most probably attributable to the exposure to higher dose 
per body weight for the females. It was postulated that this trend would be more 
pronounced for our predominantly Asian female patients (who are generally even 
lighter in weight than Caucasian counterparts).  
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 In addition to helping to resolve the abovementioned issues, the results from 
this study could provide baseline information quantifying the problem of DRPs 
among hospitalized patients receiving polypharmacy in Singapore, and contribute to 
the formulation and implementation of risk management strategies. 
 
 





 The study population used in this study is the same as that in Chapter 2. 
However, the emphasis for this chapter will be on drug-related problems acquired by 
the patients during their hospital stay, rather than those they presented with on 
admission to the hospital (Chapter 2). 
  
 As a recap, a retrospective, cross-sectional study was conducted in Alexandra 
Hospital - a 404-bed acute-care hospital in Singapore. In-patient case notes and 
medication records were used in our data collection. Subjects were included in the 
study if they were in-patients on the last two Thursdays of November and December 
2000, and who satisfied the criteria of being prescribed polypharmacy (see definition 
below). Thursday was chosen to ensure that the patients admitted over the weekend 
would have had their admitting medications checked or altered by the attending 
physicians. This would capture most DRPs amongst these hospitalized patients. 
 
Definitions 
 In this study, DRP was defined as an event or circumstance that involves a 
patient’s drug treatment that actually, or potentially, interferes with the achievement 
of an optimal outcome.48 
 
 For ADRs, the World Health Organization definition which specifies an 
adverse reaction as a reaction which is noxious and unintended, and which occurs at 
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dosages normally used for prophylaxis, diagnosis, therapy of disease, or for the 
modification of physiological function was used (WHO 1972). 
 
 Polypharmacy was defined as the daily consumption of 5 or more medications. 
Different strengths of the same drug were counted as one item. However, 
formulations of the one drug requiring different routes of administration were 
regarded as separate items. Combination drug, that is a drug with more than one 
active ingredient in it, was regarded as a single item. 
 
3.2.3 Data Collection 
 Patient’s age, gender, principal diagnosis, concomitant disease states, medical 
history, concurrent medications and dosage, and medications taken prior to admission 
were recorded. Other data collected included biochemistry and hematology results, 
microbiological culture and sensitivity tests, and plasma drug concentrations when 
these were available. Normal laboratory values for the hospital were used to 
determine the presence of abnormalities. Renal function was estimated from 
creatinine clearance.92 DRPs experienced by the patients on admission and during 
their in-patient stay, together with the suspected drugs were extracted from their 
medical records. To avoid inter-rater variation, the case notes and medication records 
of the patients were reviewed by one of the investigators and any need for 
confirmation of the decision was resolved with the other investigators. 
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3.2.4 Classification of DRPs 
 DRPs were defined as inappropriate treatments, potential drug interactions, 
inappropriate dosages, unsafe drugs for patients, and ADRs experienced by the 
patients on admission and during their in-patient stay. ADRs which occurred during 
the same period were characterized based on the drugs and drug class involved; the 
manifestations of these ADRs, and the frequency of occurrence. Due to the 
retrospective nature of the study, the ADRs and their potential causality drugs were 
extracted from patients’ medical case notes with no further evaluation and 
determination into the ADR causality.  
 
 Based on the case notes, the patients’ existing conditions were matched with 
their drug therapy. Appropriate doses of drugs, appropriate drug indications, possible 
drug interactions, and ADRs were based on drug monographs in the 42nd edition of 
the British National Formulary.93 
 
 The appropriateness of control was determined based on the physician’s 
documentation of the patient’s condition in the medical case notes, together with any 
available laboratory results. For any documentation of a poorly controlled medical 
condition, the medication records were reviewed thoroughly to determine if the poor 
control was drug-related (i.e., if the patient was receiving adequate and/or appropriate 
medication at that time). Inappropriately controlled conditions due to lack of 
medications, or lack of synergistic medications, would be classified as “additional 
therapy required”, while a drug was prescribed for no obvious indication would be 
classified as “unnecessary drug therapy”. 
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 In assessing the appropriateness in the choice of drugs, Beer’s explicit criteria 
were used to identify medications that were deemed unsuitable for use in elderly 
patients more than 65 years old.94 
 
3.2.5 Statistical analysis 
 Chi-square test was employed to test for significant difference between the age 
of patients, as well as the gender of patients and their risk of getting DRPs. Mann-
Whitney test was used to test for significant difference between the number of 
medications taken and the risk of DRPs. In all comparisons, the level of significance 
was adopted as 0.05.  
 
 The relative risks of developing ADR and DRP for geriatric patients and 
female patients were estimated from the prevalence of these events compared with 
non-geriatrics and male patients, respectively, to evaluate the propensity to develop 
the events in these patient subgroups. 
 
 




Characteristic of population 
 There were 640 in-patients during the study period. Data were collected for 
347 patients (54.2%) prescribed polypharmacy. Their age ranged from 16 to 97 years 
(mean 65.9 ± 17.7 years). Of the subjects recruited, 43% were female. Geriatric 
patients (patients more than 65 years old) made up 58.2% of our study population. 
 
Medication profile 
 The number of medications per patient ranged from 5 to 14 (mean 7.4 ± 2.1). 
Paracetamol was the most commonly used drug (33.4%) followed by two laxatives, 
senna and lactulose (prescribed in 30.3% and 29.7%, respectively). A total of 181 
patients (52.2% of our study population) were taking laxatives. Of which, 13 patients 
(3.7%) were on 3 laxatives and 80 (23.1%) on 2 laxatives simultaneously. The ten 
most commonly prescribed medicines are shown in Table 3.1. 
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Table 3.1 Ten most commonly prescribed drugs 
Drug Number of patientsa  (%)b 
Paracetamol 116 33.4 
Senna 105 30.3 
Lactulose 103 29.7 
Sangobion 70 20.2 
Aspirin 67 19.3 
Isosorbide dinitrate 55 15.9 
Potassium chloride 51 14.7 
Amlodipine 50 14.4 
Famotidine 50 14.4 
Enalapril 42 12.1 
aPatients who are receiving the drug 
bThe percentage of study population receiving the drug 
 
3.3.3 DRPs during hospital stay 
 A total of 450 DRPs were seen in the 347 study patients. The types of DRPs 
identified during the study period included: (1) inappropriate treatment (comprises 
additional therapy required, unnecessary drug therapy, and use of inappropriate drug) 
– 33.1%; (2) potential drug interactions – 34.7%; (3) inappropriate dosages – dose too 
high or dose too low – 16%; (4) unsafe drug for patients – 10.4%; and (5) ADRs  - 
5.8% (Figure 3.1). 
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Figure 3.1 Drug-related problems and their number of incidences identified in 
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 Of the 149 incidences of inappropriate treatment, 118 had an untreated 
condition that required additional therapy, with anemic patients (identified by their 
biochemistry results) making up 64.4% of this group. Another 9 patients would 
require additional drugs to improve the management of their existing medical 
conditions. For patients receiving unnecessary drug therapies, 5 had no recorded 
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medical indication for their prescribed medications and the remaining patients were 
prescribed duplicate therapies (Figure 3.2). Patients taking drugs not recommended 
for their conditions made up the remaining 17 cases of inappropriate treatment. Of 
these, 82.4% was due to usage of a particular drug when contraindicated (e.g. the use 
of propranolol in an asthmatic), and the rest due to using a drug when the condition 
was already refractory to it (e.g. using ciprofloxacin when culture and sensitivity 
results showed bacterial resistance) or when a particular drug was not even indicated 
for the condition (e.g. prescribing paracetamol for giddiness). 
 
 For inappropriate dosages, the cases encountered were wrongly prescribed 
dosages, inappropriate administration frequencies, or the serum drug concentrations 
were higher or lower than recommended ranges during therapeutic drug monitoring. 
For some patients, the dosages of their medications were deemed as too high when 
their abnormal hepatic or renal functions were taken into account (Table 3.2).  
 
Table 3.2 Dose of medication too high for existing renal or hepatic function 
Drug Impaired function Number of patients 
Enalapril Renal 4 
Metronidazole Hepatic 2 
Allopurinol Renal 1 
Cefuroxime Renal 1 
Fluoxetine Renal 1 
Tolbutamide Renal 1 
Tramadol Renal 1 
 
 Each combination of the drugs prescribed for the patients during their 
hospitalization were checked for potential interaction, and the top ten drugs/drug 
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classes that were most likely to be involved in causing drug–drug interactions are 
listed in Figure 3.3. The current study only managed to identify cases of potential 
drug interactions during hospital stay as the documentation of drugs which the 
patients were on prior to admission was not comprehensive for all the patients.  
 
Figure 3.3 Ten drugs/drug classes that were most likely to be involved in 
causing drug–drug interactions 
 
 The 47 cases of unsafe drug for patients during hospitalization were identified 
based on Beer’s criteria which documented the drugs unsuitable for use in patients 
more than 65 years old. Again, unsafe drug usage for patients on admission could not 
be identified due to limitation of documentation. Drug-pairs identified in the study 
that could give rise to potential severe interaction are shown in Table 3.3. 
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Table 3.3 Significant potential drug interactions 
Drug pair Possible effects 
Atenolol + nifedipine Severe hypotension and heart failure 
occasionally 
Phenytoin + folic acid Decrease plasma level of phenytoin 
Simvastatin + erythromycin Increase risk of myopathy 
Simvastatin + warfarin Enhanced anticoagulant effect 
SSRI + valproate Convulsion threshold lowered 
Theophylline + calcium channel blocker Possibly enhanced theophylline effect 
 
 With regards to the analysis of risk factors, there were no statistical 
correlations when age and gender were compared between patients with and without 
DRPs, both on admission and during hospital stay. However, based on Mann-Whitney 
test, the number of medications prescribed for the patients was not a risk factor for the 
presence of DRPs (p=0.119) during hospital stay, but it was a risk factor for patients 
with DRPs on admission (p=0.001). 
 
3.3.4 ADR analysis 
 There were 34 cases of identified ADRs that occurred in 33 patients (one 
patient experienced two ADRs during the study period) (Table 3.4). Patients 
suspected of experiencing an ADR were taking a mean of 8.2 (± 2.6) different 
medicines compared with those not having an ADR on a mean of 7.3 (± 2.1) 
medicines (p=0.015). Of those who experienced ADRs, 60.6% were geriatrics. This 
formed about 10% of the geriatric patients in our study, and 36.4% of these geriatric 
patients were female. 
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Table 3.4 Identified cases of adverse drug reactions 
Drug class Drugs Manifestations of ADRs Number of patients 
Coffee ground vomitus 4 
Bleeding GIT 2 




Gastric ulcer 1 
Declining renal function 1 
Chronic cough with 
wheezing 
1 
ACE inhibitor Enalapril 
Postural hypotension 1 
Hyponatremia 1 Carbamazepine 
Thrombocytopenia 1 
Phenytoin Giddiness 1 
Antiepileptic 
Valproate Tremors 1 
Hyponatremia 1 
Increased in INR 1 
Fluvoxamine 




Fluoxetine Hyponatremia 1 
Dehydration 2 Loop diuretic Frusemide 





Amlodipine Postural hypotension 2 
Generalized rash 1 Anti-platelet Ticlopidine 
Decreased in hemoglobin 1 
Analgesic / 
antipyretic 
Paracetamol Itch 1 
Antiarrythmic Procainamide Anti-phospholipid syndrome 1 
Antibiotic Ethambutol Generalized rash 1 
Antipsychotic Sulpiride Extrapyramidal side effects 1 
Beta-blocker Propranolol Asthma exacerbation 1 
Fibrinolytic Streptokinase Rigors and facial flushing 1 
Statins Simvastatin Increased in liver function 
tests 
1 
Sulphonylurea Glipizide Increased in liver function 
tests 
1 
Abbreviations: ADRs, adverse drug reactions; NSAIDs, non-steroidal anti-inflammatory 
drugs; ACE, angiotensin converting enzyme; SSRIs, selective serotonin re-uptake inhibitors; 
GIT, gastrointestinal tract; INR, international normalized ratio 
 
 Based on the results, the relative risk for geriatrics above 65 years in the 
current study to develop ADRs was 1.01 (95% CI: 0.52, 1.85), and the relative risk for 
female patients in developing ADRs was 0.79 (95% CI: 0.40, 1.55). However, when 
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the same analysis was performed for patients on major polypharmacy (10 or more 
drugs) the relative risks were 1.23 (95% CI: 0.36, 4.25) and 0.66 (95% CI: 0.21, 2.02), 
respectively, for geriatrics and female patients in developing ADRs. 
 The prevalence rates of developing DRPs and ADRs for the various patient 
subgroups during the study period are summarized in Table 3.5. 
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Table 3.5 Prevalence rates of developing DRPs and ADRs for the various patient 
subgroups 














    




























    






















    




























    













a n denotes number of patients experiencing the event, and N denotes the total number of subjects in the 
particular category 
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3.4 Discussion 
 Polypharmacy is an ubiquitous problem plaguing nearly all healthcare systems. 
Here, the occurrences of not only ADRs, but also all DRPs on admission and during 
hospitalization among patients receiving polypharmacy were investigated. An 
evaluation of the status and possibly the risk factors involved in DRPs would provide 
some basic information for working towards improving the current situation. 
 
 From the results, 63.4% of the study population (i.e., approximately 3 out of 5 
patients) had at least one DRP, albeit theoretical or actual, during their hospitalization. 
However, there was no equivalent comparison found in the published literature since 
only patients prescribed polypharmacy were recruited. Nevertheless, the high 
percentage of patients developing DRP here does highlight the need for more 
attention to the group of patients prescribed polypharmacy. 
 
 Henceforth, the DRPs experienced by the in-patient with emphasis on 
potential drug–drug interaction, appropriate dosages, and ADRs will be discussed, as 
these DRPs might have been preventable if physicians and pharmacists carried out 
proper checks. 
 
 The present analysis on DRPs showed that potential drug–drug interactions 
accounted for a substantial amount of potential drug toxicity (34.8%). Numerous drug 
combinations that resulted in modification of pharmacological action or in drug 
toxicity have been documented.95 In the present study, 59% of possible drug-drug 
interaction occurred in geriatric patients. The drugs most implicated were β-blockers 
(namely, atenolol and propranolol), nonsteroidal antiinflammatory agents (NSAIDs) 
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(including aspirin, ketoprofen, diclofenac, and mefenamic acid), and angiotensin 
converting enzyme (ACE) inhibitors. This is consistent with published data citing that 
the average number of drug-drug interactions involving anticoagulants and 
antihypertensives were significantly higher than other drug groups.96 
 
 In addition, drug-pairs in this study that could give rise to potential severe 
interaction were also identified (Table 3.3). However, it must be acknowledged that 
the judgment here is based on theoretical consideration. In clinical practice, some of 
these combinations may still be used, but the patient will need to be closely monitored 
for manifestations such as lack of therapeutic efficacy or toxicity, especially for drugs 
whose therapeutic effects may be diminished or augmented when used in those 
combinations. As drug interactions can affect patient’s clinical outcome, quality of 
life, as well as contribute to unnecessary healthcare cost, the high prevalence rate 
(~30%) in this study would make this an important area requiring further investigation. 
As the study was carried out prior to the introduction of clinical pharmacist services at 
the study hospital, future pharmacists should focus on reviewing patients’ medication 
charts and checking for potential drug interactions. 
 
 Another common aspect of DRPs is inappropriate dosages of medicines. 
Medication dosages were not adjusted for 11 patients with either renal or hepatic 
impairment. This made up 15.3% of all the patients receiving inappropriate drug 
dosages, and 2.4% of the entire DRPs in this study. Again, this might be an 
underestimation as the documentation in the patient’s case notes was not very 
comprehensive and our judgment was based on available biochemistry reports. 
Moreover, there might be further cases of renal and hepatic impairment that were 
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missed during analysis. With proper monitoring, it is possible to substantially reduce 
such incidences.  
 
 ADR is another important subset of DRPs. Nearly 10% of in-patients were 
found to have an ADR, which is higher than the ADR incidence of 6.7% found in the 
meta-analysis of 39 prospective studies from US hospitals.33 However, it was in line 
with the report from another study showing 10%–20% of hospitalized patients 
experiencing at least one ADR during their hospital stay.89 Since the current study 
was carried out only on patients prescribed polypharmacy, the only inference that 
could be drawn was that the ADR incidence was probably comparable to international 
figures. 
 
 In evaluating the drugs frequently implicated in ADRs (Table 3.4), NSAIDs 
and ACE inhibitors were ranked the highest, closely followed by antiepileptics and 
serotonin-selective reuptake inhibitors (SSRIs). The drugs implicated in the present 
study are again quite similar to what has been reported.77, 90 This congruency 
highlights that there is a rationale to focus more attention on patients prescribed 
certain drugs or drug classes.  
 
 In the attempt to identify risk factors, the study results supported published 
findings that the number of drugs taken by a patient is an important risk factor for 
ADRs. Definitely, the use of polypharmacy in patients is sometimes necessary to 
control or manage medical conditions. However, a patient may often be taking a 
multitude of medications because medications were used as substitutes for careful 
diagnostic manoeuvres or effective nonpharmacologic therapies.23 Therefore, before 
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prescribing a medication, it is important to determine if the patient’s condition is 
caused by a current medication. It defeats the purpose if additional agents are 
prescribed to deal with the symptoms of adverse drug effects and this in turn 
potentiates the problem of polypharmacy.  
 
 The study also attempted to estimate the relative risk of developing ADRs 
using the age and gender of patients as risk factors. So far, we know of only one study 
that determined the relative risk of age (as a risk factor) in developing ADR in 
patients on major polypharmacy.91 The establishment and knowledge of the relative 
importance of various risk indicators would lead to better risk management strategy 
among different patient subgroups. 
 
 From the analysis for patients already receiving polypharmacy, it was found 
that geriatrics had a similar risk in experiencing an ADR compared with non-
geriatrics. However, this relative risk was increased to 1.23 if only patients who were 
on major polypharmacy (10 drugs or more) were included. Although no statistically 
significant correlation between increasing age and increased likelihood of developing 
ADR was observed, this could be due to the small sample size.  
 
 Likewise, where gender comparison is concerned, the study results showed 
that female patients did not have a higher risk in developing ADRs when compared 
with male patients. This finding is contrary to those reported from Denmark,87 and the 
Netherlands,28 where the relative risk in developing ADRs for female patients was 
1.57 (95% CI: 1.15, 2.14) and 1.46 (95% CI: 1.09, 1.75), respectively. However, there 
were some differences in patient characteristics between the studies. In the Danish 
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study, a total of 1999 patients of all ages, regardless of whether they were receiving 
polypharmacy or not were recruited.87 For the Dutch study, 2185 geriatric patients (65 
years and older) prescribed polypharmacy were recruited, and polypharmacy was 
defined as long-term use of 2 or more drugs. In comparison, the current study 
inclusion criteria for polypharmacy, defined as 5 or more drugs, had restricted the 
number of eligible patients during the study period. The much bigger sample sizes in 
the previous two studies allowed them to be more sensitive in detecting the 
correlation between female gender and the risk of developing ADRs. 
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3.5 Conclusions 
In summary, several observations could be drawn from the study results:  
1. The study results established that the situation of drug therapy related 
problems in hospitalized patients receiving polypharmacy in Singapore is 
comparable to that occurring in other developed countries. One important 
interpretation of this would be that although the problem of DRP has been 
studied and reported for the past twenty years, lessons and experiences 
from these studies have not exactly been translated into effective 
management of these problems. Further investigations are required to see 
what the underlying problem is in the current healthcare operating system 
that is causing this failure. 
2. Regarding risk factors, the study results showed that among patients with 
polypharmacy, age and gender may not be as important as the number of 
drugs prescribed as predictors of experiencing a DRP. In our case, neither 
older nor female patients show higher risk of developing DRP, but this 
may be confounded by the inclusion criteria. A similar trend was observed 
in the developing of ADRs. 
3. The results also showed that the drugs causing DRPs in this study are 
similar to those in overseas studies. Through identifying drugs that are 
most likely to cause DRPs, healthcare professionals could spend more time 
monitoring patients prescribed these drugs.  
 
 Based on these findings, the researcher would advocate applying the 20/80 
principle in business management into clinical risk management here. By identifying 
and properly managing the small percentage of high-risk patients (such as those with 
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risk factors for developing DRPs and those prescribed drugs commonly associated 
with DRPs), most of these DRPs could be minimized or prevented. The researchers 
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4.1 Introduction 
 Drug-related problems (DRPs) are consequences which are different from the 
intended pharmacotherapeutic effect of the drugs involved.2 Due to their association 
with increased rates of morbidity and mortality, DRPs continue to be a major problem 
faced by healthcare institutions worldwide.2, 6-8 Inappropriate prescribing of 
medications, ADRs and drug interactions may cause increased morbidity and 
mortality, and treating these iatrogenic complications further burdens the health care 
system.6 This is in view of patients requiring more nursing care, more attention by the 
attending physician, and possibly additional drugs to treat the resulting adverse 
reaction or interaction.7 All these inevitably lower the quality of life of the patient. 
Moreover, the extent and cost of drug related morbidity and mortality are of great 
importance to health care practitioners, administrators, patients and society as a 
whole.2 
 
 Despite the efforts of healthcare professionals in reducing DRPs, it is 
considered that a large proportion of these DRPs are preventable,8 In the last decade, 
pharmacists have contributed to improvements in the areas of drug therapy and patient 
safety. There has been a paradigm shift from their traditional roles of distribution and 
dispensing of medications to the active involvement in the direct provision of 
pharmaceutical care.37-47 
 
 There are many definitions of pharmaceutical care.39, 48, 97, 98 However, despite 
the slight difference in definition, one common fundamental element is that 
pharmaceutical care implies communicating and reaching a consensus between the 
patients and physician or other healthcare professionals regarding pharmacotherapy.39 
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With such a shift in approach in health care delivery, the pharmacists will need to go 
beyond their traditional roles of dispensing and distributory function and be very 
much more involved in the identification and solutions of problems related to drugs, 
and to prevent drug-related problems from occurring. Some of these interventions 
carried out by the pharmacists would include advising of appropriate surgical 
antibiotic prophylaxis, performing pharmacokinetic monitoring, initiation and 
discontinuation of drug therapy, suggesting of alternative pharmacotherapy, as well as 
influencing the modification of drugs’ dose, frequency and route of administration.37, 
39 Such pharmacist interventions strive to achieve a rationale use of drugs, and 
pharmacists actually have carried out most of these either regularly or sporadically. 
However, for this to take place effectively and systematically, pharmacists have to 
participate actively and coordinate with other health-care professionals in 
multidisciplinary care.37, 39-44 Going on clinical ward rounds as a member of the 
patient care team will allow the pharmacists to provide such services most 
efficiently.40 The pharmacists will be able to provide real time response or consult and 
intervene immediately when the need arises, rather than to spend time checking and 
correcting orders after they have been sent to the pharmacy. 
 
 The provision of pharmaceutical care can reduce the number of adverse drug 
events and the length of hospital stay.48 All these would translate to cost savings and 
cost avoidance in the medical institutions as well as for the patients.39, 41, 44 The 
quantum of the cost savings could be quite substantial and has been estimated by 
several overseas studies. In 1997, Mutnick et al. presented the results of 4648 
interventions carried out by 50 pharmacists during a 9 months study at a 849-bed 
institution.44 These interventions were based on the pharmacist’s evaluation of the 
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patient, the condition involved, and the appropriateness of the drug therapy prescribed. 
Of these interventions, 87% were accepted by the medical staff, and these accepted 
interventions represent a net therapy cost saving of US$487,833, as well as a cost 
avoidance of US$158,563 achieved by preventing a potential net 371.9 additional 
hospital days. 
 
 In a more recent study published in 2003, Galindo et al. analysed 3136 
pharmacists’ interventions that were collected prospectively for 6 months in a 330-
bed acute hospital.39 Of the recommendations made by the pharmacists in their 
interventions, 88.8% was accepted by the medical practitioners and financially they 
represented a cost saving of €129,058.31. 
 
 In Singapore, hospital pharmacists are starting to play a more significant role 
in improving the quality of medical care for patients by actively identifying and 
solving DRPs. Although participation of pharmacists on ward rounds in hospitals is 
relatively common, there is a lack of regular schedule for participating in ward rounds 
in conjunction with a primary patient care team. However, the clinical and financial 
impact of the inclusion of a pharmacist as a regular member of team doing the clinical 
ward round has not been evaluated or studied. This stems from the fact that a low 
pharmacist-to-patient ratio still prevails here, and the pharmacists are over-worked 
just dealing with the traditional role and function of distribution and dispensing of 
medications, thus preventing many of them from participating as a regular member of 
the clinical ward round team. Nevertheless, pharmacists do perform routine reviews 
of patients’ medication records to check their drugs, dosing regimen, drug 
compatibility, drug-drug/food interactions, etc as part of their drug distribution 
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responsibility. On occasions when DRPs or potential DRPs were identified when 
going through patient’s medication or medical record, the pharmacists would 
approach the primary care team to alert them about the problem and suggest a solution 
for it. 
 
 Since economic constraints dictate that the impact of all such pharmacist 
services on patient care be demonstrated to ensure the cost-effectiveness and best use 
of pharmacist services and manpower, this study aimed to investigate the impact of 
the pharmacist’s participation in a physician-pharmacist review team. If the current 
study is able to demonstrate the reduction in pharmacy costs and decreased length of 
stay of patients with the active participation of pharmacists as regular member in 
doctors’ ward rounds, it would further enhance the roles of pharmacists in the care 
and clinical management of patients. Evaluating the cost-savings as a result of the 
successful interventions made by these physician-pharmacist review teams will also 
help to justify the cost-effectiveness for the hospital to endorse such services. Hence, 
the information obtained from this study would be able to lay the groundwork to 
allow further streamlining of clinical pharmacist services and how they can be 
provided more efficiently. This would also assist in allocating of valuable resources 
from the management perspective, and lead to further improvement in clinical and 
economic outcomes in patients. 
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4.2 Methods 
 The prospective, controlled study was carried out in Alexandra Hospital, an 
acute care hospital (440 beds) in Singapore. In Singapore, 80% of hospital care is 
provided by the publicly funded health care institutions which include Alexandra 
Hospital.  
 
 Four wards were chosen for this study, serving both as the control and study 
arms. These wards were chosen as a result of their similarity in patient-mix (gender 
and age group), as well as discipline-mix (all belonged to general medicine discipline). 
General medicine discipline was chosen for this study because patients in this 
discipline made up a large portion of the hospital in-patient population.  
 
 Due to the constraint in the number of in-patient pharmacists available to 
participate daily in this pilot study of physician-pharmacist review team during the 
study period, a maximum of only two pharmacists could participate in the study at 
any one time. Hence, only one or two wards can be studied each time. This was a 
trade-off after considering the number of available pharmacists at the study site and 
the number of pharmacists required to handle day to day pharmacy operations like 
distribution of drugs to the wards and dispensing of medications to discharged 
patients. 
 
 The enrolment target for this study was at least 660 patients, i.e. 330 patients 
each in the control and study groups. This sample size was derived based on 
biostatistical calculations as follows. If there were 300 patients in each group, at an a 
priori alpha level of 0.05 and power of 80%, a difference in response rate of 25% 
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could be detected. That would translate to having a significant difference if the length 
of stay was reduced by at least 0.93 days; if the difference in pharmacy cost was at 
least S$275; and if the difference in hospital charge was at least S$1000 (before any 
form of government subsidy). This worked out to a total of 600 patients from both 
groups. However, in order to accommodate drop-outs (see next paragraph) where the 
drop-out rate was estimated at 10%, the recruitment number was increased to 660 
patients. 
 
 The inclusion criterion for this study was patients who were admitted as in-
patient in the selected wards on the stipulated days of study. Patients who died, 
changed medical discipline, transferred out of the ward/hospital, absconded from the 
hospital or were discharged at own risk (meaning patients who asked for discharge 
even when the physicians feel that they are not ready for that) were excluded from the 
analysis. 
 
4.2.1 Study group 
 During the study period from January 2005 to April 2005, the in-patient 
pharmacists who were involved would participate in ward rounds together with the 
medical team on a daily basis, except on weekends, in the selected wards. Prior to the 
rounds, the pharmacist reviewed all patient profiles and relevant data, including the 
progress and consultation notes, and note down any modification of drug regimen to 
be recommended. They also interviewed patients with regards to their drug history 
and drug allergy profile when required. The relevant information would be 
highlighted to the physician teams during ward rounds. For newly admitted patients 
(during the night), the pharmacist would visit them with the physicians. The 
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pharmacist would take this chance to evaluate the drug treatment given to the new 
patients and suggested relevant changes, if any. Any existing or potential drug related 
problems would also be identified by the pharmacist and highlighted to the medical 
team. 
 
4.2.2 Control group 
 The control group was run independently from the study group. During the 
same period, the other wards that were matched with the study group in terms of 
patient-mix and specialty-mix were used as control. The difference in the control 
group was that pharmacists did not attend ward rounds with the medical team. 
Nevertheless, services that were already provided by the pharmacists still continued as 
per normal. Hence, the pharmacists would still review in-patient medication records 
independently for any existing or potential drug related problems, as well as sub-
optimal pharmacotherapeutic regime. These were highlighted to the medical team 
either via telephone call or by pasting a note in the medication/medical records for the 
relevant medical teams to follow-up on. 
 
 In order to reduce bias due to different working patterns and clinical 
experience, the four pharmacists who participated in this study were rotated between 
the study and control group. At any one time, there was only one pharmacist and one 
study ward involved due to shortage in manpower. However, one control ward would 
always run concurrently with a study ward. 
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4.2.3 Types of interventions 
 The types of interventions carried out by the pharmacists in both the study and 
control group were tabulated in Table 4.1.  
 
 Based on the type of intervention carried out, the percentage of 
recommendations for the intervention accepted by the physicians would also be 
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Table 4.1 Type of interventions carried out by pharmacists during the study 
 
A. Review drug administration dose regimen  
 Examples 
1. Wrong dose 
2. Wrong dosage form/strength 
3. Wrong frequency/rate 
4. Wrong duration 
5. Wrong route 
6. Inappropriate duration of administration – medication to be stopped but 
not off. 
7. Convert from IV to oral 
8. Recommendation for blood levels of drugs to be taken 
 
B. Identify adverse drug reactions and suggest alternatives 
 
C. Review drug selection indications  
 Examples 
1. Drug used without medical indications (discontinue drug) 
2. Inappropriate drug chosen (drug substitution) 
3. Therapeutic duplication 
4. Drug allergy 
5. Patient prescribed a drug that should not be given because of his medical 
condition 
6. Drug interactions 
7. Financial impact (drug too expensive, suggest drug substitute) 
 
D. Indication without drugs e.g. 
Untreated medical conditions (addition of drug or other therapy) 
 
E. Follow-up on incomplete medication history 
 
F. Provide drug information to physician 
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4.2.4 Data collection 
During the study period, patients’ demographic data as well as information on the 
types of interventions by pharmacists and the size of each patient’s hospital discharge 
charge were collected. These data were collected from: 
1. Records in patients’ in-patient case-notes and in-patient medication 
records for data like patients’ demographics, the types and number of 
medications patients were on as well as the patient’s length of stay. 
2. Therapeutic intervention recording forms used by the pharmacy 
department (See Figure 4.1). These documentations by the pharmacists 
would provide the details of the type of interventions they initiated and 
whether these were accepted by the physicians. 
3. Patient’s hospital charge provided by the finance department. This was for 
getting information on the drug cost for each patient, as well as the total 
hospitalization charge of the patient. 
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4.2.5 Outcome measures 
 The effects of pharmacist’s participation in a physician-pharmacist review 
team were assessed with three measures:  
1. length of hospital stay,  
2. total pharmacy costs incurred by patients during their stay in the hospital; 
and  
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3. total hospital costs incurred by patients during their stay in the hospital.  
 
 These three factors were ascertained in both the study and control groups, and 
a comparison was made. 
 
 The rationale for choosing these outcomes was based on the premise that at 
the population or group level, any improvement in clinical outcomes would be 
reflected in the overall length of stay, and any financial and economic impact of the 
intervention would be reflected in the total drug cost and the final hospital charge 
(which would also included laboratory costs and other procedure costs).   
 
 However, since the nature of interventions carried out by pharmacist would 
mainly concern drug-related problems, the immediate impact would logically be more 
observable in overall drug cost between the two groups.   Hence, the impact on the 
drug cost would be the major outcome variables in this study.   The other two 
outcomes would be considered as secondary outcome variables as there are many 
other factors that may influence them.   Those influencing factors would be discussed 
in the discussion section of this chapter. 
 
4.2.6 Analysis 
 The average length of stay for the patients in each group was calculated by 
taking the mean of the number of hospital stay of the individual patients. 
 
 To calculate the mean drug cost for the study group, the total drug cost over 
the length of stay for each patient was used to derive the drug cost per day. Based on 
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the drug costs calculated for all the patients, an average drug cost per day was 
calculated.  
 
 Using the average drug cost per day and average length of stay for the study 
group, the total mean drug costs per patient in the study group (Coststudy) was 
calculated. The calculation to get the drug costs per patient in the control group (Cost-
control) was performed likewise.  
 
 The formulae used for calculations are shown in Table 4.2. From the above, 
the total cost savings (if any) between the study and the control groups could be 
calculated. 
 
 In order to calculate the total cost savings for the study group where the total 
hospital charges to the patient is concerned, the average hospital charges per patient in 
each group was first determined. The difference between the average hospital charges 
between the control group and the study group would give the hospital charge savings 
per patient in the study group. The total hospital charge savings of the study group can 
be calculated using the difference in hospital charges as mentioned above multiplied 
by the number of patients in the study group (See Table 4.3). However, in order to 
accommodate the difference in level of subsidy that are being provided by the 
government to the different classes of patients, the hospital charges for each patient 
was adjusted to reflect the true level before government subsidy. Our study 
encompassed patients from class B2 wards, as well as class C wards. Currently, class 
B2 patients are given a 65% government subsidy on their charges, whereas class C are 
given a subsidy of 80%. 
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Table 4.2 Calculating cost savings in study group over control group 
 
For study group: 
 For each patient, take total drug cost / length of stay to get drug cost per day, 
DrugCostday(study). 
 
 Based on all the drug cost per day, take an average drug charge per day 
AvDrugCostday(study). 
 
 Use the AvDrugCostday(study) x average length of stay of the group to get drug 
cost for the study group, Coststudy. 
 
For control group: 
  For each patient, take total drug cost / length of stay to get drug cost per 
day, DrugCostday(control). 
 
 Based on all the drug cost per day, take an average drug charge per day 
AvDrugCostday(control). 
 
 Use the AvDrugCostday(control) x average length of stay of the group to get 
drug cost for the control group, Costcontrol. 
 
Therefore, drug cost savings per person Costsavings = Costcontrol - Costintervention 
Total drug cost savings in study group = Costsavings x number of people in study 
group 
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Table 4.3 Calculating hospital charge saving in study group over control group 
 
Total mean hospital charges per patient in the study group, HospChargelstudy  
= Sum of hospital charges of all the patients in the study group / number of patient 
in the study group 
 
Likewise, total mean hospital charges per patient in the control group, 
HospChargecontrol  
= Sum of hospital charges of all the patients in the control group / number of patient 
in the control group 
 
The mean hospital charge savings per patient, HospChargesavings = HospChargecontrol 
- HospChargestudy 
 
Total hospital charge savings in study group = HospChargesavings x number of 
people in study group 
 
 In order to quantify the financial impact of the inclusion of a pharmacist in the 
regular clinical ward round team, the drug cost savings per patient, cost-benefit ratio, 
as well as the net annual return on the investment of a pharmacist in such physician-
pharmacist review teams were also calculated. The formulae and the cost used to 
calculate these values are detailed as in Table 4.4. 
 
 
Chapter 4: Impact of Physicians-Pharmacists Review Team 74
Table 4.4 Calculating the net annual return on investment in one pharmacist 
 
Cost of pharmacist working on the study arm: 
Average annual salary for one pharmacist = S$36,000 (this figure is obtained from 
the Human Resource Department of Alexandra Hospital) 
Proportion of time spent each day on this intervention work = 20% (about 1.5 hours 
out of 8 hours; based on the actual time spent by the pharmacist in a clinical ward 
round) 
Number of months which the study took place = 4 months (one third of a year) 
Hence, total cost of employing the pharmacist to do the study for 4 months 
= [(S$36000 / 3] x 20%  
= S$2,400 
 
Calculation of Cost-Benefit Ratio  
1. Based on savings in drug costs, cost-benefit ratio = total drug cost savings 
in study group / $2400 
2. Based on savings in hospital charges, cost-benefit ratio = total hospital 
charge savings in study group / $2400 
Net annual return on investment in one pharmacist  
1. Based on savings in drug costs = Total annual drug cost savings in study 
group – Annual cost of employing a pharmacist 
2. Based on savings in hospital charges = Total annual hospital charge savings 
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 A sensitivity analysis was also performed to test the robustness of the 
conclusion from the data obtained in this study. The sensitivity analysis was 
performed by evaluating the different cost-benefit ratios obtained by using the 
extreme values in cost differences between the control and study groups. 
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4.3 Results 
 A total of 795 patients (388 in control group and 407 in study group) were 
enrolled in the current study.  
 
 However, there were 23 and 46 patients in the control and study group, 
respectively who were subsequently excluded from the study as they fell into the 
exclusion criteria which were stated earlier under the methods section.  
 
 A breakdown of why these patients are excluded can be seen in Table 4.5. 
With that, 726 patients were left for the data analysis segment of this study, 365 in the 
control group and 361 in the study group. 
 
Table 4.5 Reasons for eventual exclusion from the study 
Reasons Control group 
(n = 23) 
Study group 
(n = 46) 
Absconded from the hospital 
 
1 2 
Patient requested for discharge even when 




Change of discipline 
 
2 12 
Change of ward 
 
9 11 
Transferred to another hospital 
 
5 7 
Patient died during study 
 
5 8 
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 The patient populations for both groups were comparable. The age range for 
the control group was 18 – 80 years old (mean: 52.5 years old; SD: 15.8) and 44.0% 
of the patients were female. In the study group, the ages of the patients ranged from 
16 – 100 years old (mean: 51.1 years old; SD: 17.0 years old) and 47.3% of the 
patients were made up of females. All these patients were from the medical discipline 
and there were no significant difference between the two groups where patients’ age 
(p=0.989) and gender (p=0.374) were concerned.  
 
4.3.1 Average length of Stay 
 The average length of stay of the control group was 5.26 days (SD = 5.10 days; 
range 1 – 34 days) and that of the study group was 5.02 days (SD = 5.60; range 1 – 44 
days).  
 
 The difference in length of stay between the two groups was 0.24 days more in 
the control group and this is statistically not significant (p = 0.550). The above data 
are summarized in Table 4.6. 
 
Table 4.6 Patient population in the two groups 
 Control group  
(n = 365) 
Study group  




18 – 80 
(52.5; 15.8) 
16 – 100 
(51.1; 17.0) 
Percentage of females/% 
 
44.0 47.3 
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4.3.2 Interventions carried out during the study period 
 An analysis of the data collected showed that a total of 202 interventions were 
performed during the study period, of which 15 came from the control group and 187 
were from the study group. This worked out to about 0.13 interventions per day in the 
control group and 1.56 interventions per day in the study group.  
 
 The most common intervention carried out by the pharmacists in the control 
group was correcting erroneous drug dosage prescribed, while the most common 
intervention carried out by the pharmacists in the study group were to prevent 
presence of untreated condition (i.e. indication without drugs) (20.6%), to ensure 
complete medication history taking (12.8%) and to ensure the most appropriate drug 
was chosen for the patient (10.6%). 
 
 Of the recommendations from these interventions, 100% from the control 
group (all 15 interventions) and 96.3% from the study group (180 out of 187 
interventions) were accepted by the physicians. There is no statistically significant 
difference between the acceptance rates for the two groups (χ2 = 0.582). A breakdown 
of the accepted interventions for the control and study groups is shown in Figures 4.2 
and 4.3, respectively. 
 
 Following these interventions, the number and types of DRPs prevented can 
be seen in Figure 4.4 (for control group) and Figure 4.5 (for study group). Hence, the 
number of drug related problems prevented in the study group was about 11 times 
more than that in the control group. 
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Figure 4.2 Types of intervention performed in the control group (n = 15) 
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Figure 4.4 Types of drug related problems prevented in the control group (n = 
 
15) 
igure 4.5 Types of drug related problems prevented in the study group (n = 
.3.3 Costs analysis 
 In the control group, the total mean drug cost per patient was S$158.02 (95% 
CI: S$137.09 – S$178.95), as opposed to a mean of S$119.03 (95% CI: S$103.29 – 
S$134.78) in the study group. Based on this, the cost savings of S$38.99 (95% CI: 
S$12.84 – S$65.14) per patient in the study group as compared to the control group 
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 Hence during the 4 months of study, the total drug cost savings in study group 
was S$14,036.40. The drug costs used in these calculations were actual drug costs 
rior to any form of subsidy. Such costs reflect more accurately the value of drug 
. Hence based on the charges to the 
atients before subsidy, the average total hospital charge per patient in the control 
 team would help bring about a cost-benefit ratio (based 
n savings in drug costs) of 5.85. With a simple linear projection using the total drug 
sponding net 
p
resources consumed than do subsidized charges. 
 
 Where hospital charges were concerned, the researchers worked entirely on 
the charges which had been corrected for subsidy
p
group was S$2,364.52 (SD: S$3,264.46; range: S$168.57 – S$45,655), whereas that 
in the study group was S$2,180.16 (SD: S$2,966.16; range: S$165.23 – S$26,947.95). 
Even though the difference between the two groups is not statistically significant 
(p=0.426), there is a trend in favour of the study group.  Based on the difference in 
mean charge sizes, a saving of S$66,373.20 in the study group during the 4-month 
study period would be realized. This would still represent a sizeable amount of 
savings for the study group.  
 
 Based on an average annual salary of S$36,000 for one pharmacist, the service 
of a pharmacist in the review
o
cost savings in 4 months, the drug cost savings on an annual basis will work out to be 
S$42,109.20. Hence, the net annual return on investing in one pharmacist to perform 
such a function based on total drug cost savings would be S$34,909.20. 
 
 When the above calculations were performed using the savings in hospital 
charge, the cost-benefit ratio derived would be 27.66, and the corre
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annual return (based on savings in hospital charge) on investing in a pharmacist to 
4.3.4 Sensitivity Analysis 
 The above cost-benefit ratios were calculated based on the pharmacist 
spending 20% of the total working hours participating in the review team. If a 
conserv ade by keeping the drug cost savings achieved annually 
nstan
perform such clinical service would be S$191,919.60. 
  
ative estimation is m
co t, but to vary the time spent by the pharmacist instead, the cost-benefit ratios 
calculated can be seen in Table 4.7. This table presents a series of sensitivity analyses 
that was carried out using extreme values obtained from the 95% confidence interval 
of the total drug cost savings. As such, the worst-case and best-case scenarios of 
having a pharmacist on board the review team were hypothetically tested out.  
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Total drug cost 
savings (S$) 
Annual total drug 
cost savings (S$) 
Cost-benefit 
ratio* 












30 38.99 42,109.20 3.90 
30 12.84 13,867.20 1.28 
30 65.14 70,351.20 6.51 
40 38.99 42,109.20 2.92 
40 12.84 13,867.20 0.96 
40 65.14 70,351.20 4.89 
50 38.99 42,109.20 2.34 
50 12.84 13,867.20 0.77 
50 65.14 70,351.20 3.91 
*Calculated based on the formula given in Table 4.4
  
 In interpreting the estimated cost-benefit ratio, a ratio larger than 1 
demonstrates that it is beneficial to have the pharmacist as part of the review team. 
From the sensitivity analyses performed, there are two cost-benefit ratios in the afore 
table that are smaller than the value 1. In the first instant, it may seem that it is not 
always cost effective to have a pharmacist on board the review team under those 
circumstances.  However, a Monte Carlo simulation of 10,000 trials showed that in 
the case when the pharmacist spent 40% of his or her working hours doing clinic 
rounds (i.e. double the amount of time as observed during the study period), the 
 
Chapter 4: Impact of Physicians-Pharmacists Review Team 84
probability of a cost-benefit ratio of less than one occurring is only 0.95%. In other 
words, 99.05% of the time, it will still be cost effective to have a pharmacist under 
those circumstances. When a similar Monte Carlo simulation is performed for the 
case assuming the pharmacist spent 50% of the working hours doing clinical rounds 
(i.e. two and a half times that observed in the study), the probability of a cost-benefit 
ratio being above the value 1 still stands at 92.74%.  
 
 The above sensitivity analyses showed that even when a conservative estimate 
is made by keeping the drug cost savings achieved annually constant and increasing 
the amount of time spent by the pharmacist on clinical involvement, the cost-benefit 
ratios were still favourable. Thereby, it is still beneficial to have the pharmacists on 
physicians-pharmacists review teams. 
 
 In the case of evaluating the robustness of cost-benefit ratios calculated from 
the total hospital charge savings, sensitivity analysis was only performed on the 
extreme values in the 95% confidence interval for the total hospital charge savings per 
patient between the two groups. The results obtained are presented in Table 4.8. 
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*Calculated based on the formula given in Table 4.4
 The calculated possible cost-benefit ratios ranging from negative to positive 
values would mean that it would not always be cost-effective to include a pharmacist 
in the team. Using an approach for estimating the probability of such non cost-
effective events occurring, Monte Carlo simulation of 10,000 trials was once again 
performed. The results obtained showed that the probability of having a cost-benefit 
ratio less than 1 (meaning not cost-effective) would be 30.56%. In other words, the 
probability of having a cost-benefit ratio of more than 1 will be around 70% even 
when difference in total hospital charges between the two groups are compared. 
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4.4 Discussion 
 In the past two decades, the pharmacy profession has undergone a paradigm 
shift where the main role in the healthcare industry is concerned. Instead of spending 
the majority of their working hours preparing and dispensing medications, 
pharmacists are beginning to focus more on evaluating drug regimens and prospective 
monitoring of patients’ responses to drug therapy.99 The pharmaceutical care concept 
described by Hepler and Strand is gaining greater acceptance in today’s healthcare 
industry.48 Today, in many countries, pharmacists are participating more actively in 
the delivery of health care, and are beginning to take joint responsibility for the 
outcomes in drug therapy. Hence, other than fulfilling the traditional role of ensuring 
that the correct drug product is delivered to the correct patient in a timely manner, the 
role of the pharmacist has expanded to include many scopes of pharmaceutical 
services. Furthermore, pharmacists nowadays do not only work independently but 
also form close and complementary working relationships with physicians, nurses and 
other paramedical personnel in delivering optimal drug therapy to the patients.97 
 
 From the study results, the pharmacists carried out a total of 202 interventions, 
96.5% of the recommendations from these interventions were accepted by the 
physicians. This high rate of acceptance showed that the suggestions made by the 
pharmacists were valued as beneficial for the drug therapy of the patients in 
Singapore. As shown by the breakdown of the accepted interventions as presented in 
Figures 4.2 and 4.3, it can be seen that more interventions were carried out when there 
was active pharmacists’ participation during clinical ward rounds together with other 
health care professionals (1.56 interventions per day for just the ward involved in the 
study) as compared to when the pharmacists do reviews of the patients’ medical and 
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medication records on their own (0.13 interventions per day for the matched control 
ward). This is important to highlight that under the operational mode of the current 
system, pharmacists in Singapore hardly have the time to do proper intervention work 
to help improve patient outcomes. Moreover when going on ward rounds as a team, 
the pharmacists would have clearer information and therefore better understanding of 
the patients’ medical conditions, what were the treatment plans for the individual 
patients and what were the monitoring parameters which the physicians were laying 
out for the patients as compared to reading the medical case-notes as certain 
documentation may not be comprehensive enough. Hence, if the pharmacists had any 
suggestions or recommendations to make about the drug regime for the patients they 
could raise it during the rounds itself. Physicians might be more receptive to such 
suggestions when they hear it in person and have a chance to clarify any doubts they 
have with the pharmacists rather than when the pharmacists leave notes in the 
medication records for the physicians to read and approve. The current study results 
reinforced the findings from overseas studies that more effective interventions could 
be carried out by the pharmacists during such rounds since they would have a chance 
to find out more about patients’ past and existing conditions.37, 39-44 With the better 
understanding, the pharmacist would be able to make more meaningful and relevant 
recommendations regarding the patient’s pharmacotherapy. This is evident from the 
difference in sheer number of interventions carried out by the study and control 
groups. 
 
 The type of interventions carried out by the pharmacists in the control and 
study groups during the study period reinforces the above inference. From Figure 4.2, 
correcting of wrong drug dosage was the most common drug problem that the 
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pharmacists in the control group identified and intervened on. This may be because 
without any extensive background knowledge of the patients, their medical conditions 
and all, there is limitation to how much the pharmacists can intervene. Singling out 
wrong dosage may be one of the easier and most obvious interventions in such a 
scenario. However, as can be seen in Figure 4.3, the types of intervention performed 
by the pharmacists in the study group were a lot more varied and extensive. The most 
common drug related problem intervened upon by the pharmacists in the study group 
was ‘Indication without drugs’. This meant that the patients had existing medical 
conditions that can be relieved or treated by a drug but the patients were not 
prescribed the required medication. Some of these untreated medical conditions were 
anaemia, gastric discomforts, cough, presence of phlegm and asthmatic patients who 
were not given a reliever inhaler to use when they experienced their asthma 
exacerbations. There were also cases of patients who had medications ceased prior to 
undergoing medical procedures but their medications were not restarted after they had 
undergone the procedures. One example was a patient who had to cease his metformin 
tablets before taking an IV contrast media. However, the physicians did not re-start 
his metformin doses after he had completed his procedure. 
 
 The second most commonly intervened problem by the pharmacists in the 
study group was ‘incomplete medication history’. In such cases, the patients had 
previous medical follow-up with private clinics, polyclinics or other hospitals’ 
specialist clinics. These patients were not aware of what medications they were 
prescribed prior to the admission. The physicians treating these patients did not 
retrieve their previous medication histories and were either prescribing empiric 
medications or simply treating the conditions which the patients were warded for 
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without regards for their other existing medical conditions. The pharmacists were 
there to assist in getting patients’ previous medication records and ensure that the 
patients had their usual supply of medicines even when they are warded. This, as well 
as the previous problem of medical conditions without an appropriate drug do require 
a great deal more interaction with the patients or the physicians, and would have been 
difficult and in fact close to impossible to be identified by the pharmacists if they had 
not gone for the rounds with the physicians. 
 
 ‘Inappropriate drug chosen’ was the third most common intervention 
performed by the pharmacists in the study group. With the chance to be present when 
the physicians were examining the patients and with first hand knowledge of what the 
physicians intend to treat the patient for, the pharmacists could recommend an even 
more appropriate choice of therapy for the patient if the physicians happened to select 
otherwise. An example of such a case during the study was when the physician gave 
only a cough suppressant to a patient who had very thick phlegm. The pharmacist 
suggested for the patient to be prescribed a mucolytic agent and only to be given the 
cough suppressant at night to ensure good sleep. 
 
 As mentioned, there were more types of drug related problems intervened by 
the pharmacists in the study group compared to that in the control group. Two of the 
more common drug related problems that were seen in the additional list that occurred 
only in the study group included ‘patient prescribed a contraindicated drug’ and 
‘information provided for administration/therapy’. Once again, these two problems 
would not have been easy to recognize if not because the pharmacists were around 
when the physicians were examining the patient and deciding on drug therapy. 
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‘Patient prescribed a contraindicated drug’ made up 8% of the total interventions 
performed in the study group. Though this percentage may not be high, dire 
consequences might have occurred if these were not identified. Likewise, without the 
intervention of ‘information provided for administration/therapy’ carried out by the 
pharmacists, there may be a lack of efficacy of the treatment prescribed. 
 
 Following these interventions, the drug related problems that were prevented 
as a result could be seen in Figures 4.4 and 4.5 for the control group and study group, 
respectively. As mentioned, the number of drug related problems prevented in the 
study group is about 11 times higher than that in the control group. In the study group, 
the top three problems that were prevented were, in descending order, ‘prevented 
inappropriate therapy’ (39%), ‘prevented a lack of therapy’ (31%) and ‘prevented the 
administration of an incorrect drug’ (12%). These preventions could be translated to 
ensuring optimal drug therapies for the patients and their associated medical 
conditions. In fact, lack of therapy of a regime or the administration of an incorrect 
drug is very detrimental to the patients’ health as they can either worsen existing 
medical condition or even cause fatalities. On the whole, such prevention helped the 
patients to achieve a better quality of life. 
 
 The three types of drug related problems that were prevented only in the study 
group but not in the control group were ‘prevented adverse drug event’ (4%), 
‘prevented or minimized drug incompatibility’ (3%) and ‘prevented unnecessary cost 
of medications’ (2%). Although the number of adverse drug events prevented was 
small, it is of no doubt important due to the possibly dreadful consequence which the 
patient may suffer, not forgetting the additional costs involved in managing the 
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adverse events. Pharmacists in the team could also perform immediate 
recommendation for a cheaper drug alternative if they felt that both drugs had equal 
beneficial effects on the patients. This would help the patient save on unnecessary 
drug costs. 
 
 Although the number of drug related problems detected and problems 
prevented in the study group were higher in the study group, this did not seem to 
impact significantly on the average length of stay between the two groups - 5.26 days 
in the control group versus 5.02 days in the study group. There was essentially no 
significant difference in the average length of stay between these two groups. 
However, this observation would not necessarily be interpreted as a lack of impact on 
clinical outcomes by the interventions carried out by the pharmacists. In clinical 
practice, the length of stay in the hospital may also be influenced by other factors such 
as discharge protocol and policy, availability of step-down facilities etc. which would 
not be immediately be affected by any of the improved outcomes due to interventions 
by the pharmacists.    
 
 Therefore, although it was reported that there was no significant difference in 
the length of stay between the two groups, this lack of difference might be due to 
inherent nature of the healthcare delivery system. Even though the pharmacists had 
reduced the occurrence of DRPs in the study group, discharge policies and clinical 
pathways which the physicians adhered to were not changed immediately as a result 
of this study. The impact of the interventions carried out by pharmacists, which might 
realize in improved outcomes in the patients, would require a much longer time to be 
translated into changes in clinical protocol and policy. 
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 Despite the fact that there was no difference in the average length of stay, it 
was found that during the 4 months of study, the total drug cost savings achieved in 
the study group was S$14,036.40. Although there was no statistically significant 
difference in total hospital charges between the two groups, there is a trend in favour 
of the study group which could be estimated to result in a cost saving for the study 
group of S$66,373.20. However, what would be more informative for the health 
administrators and providers would be the cost-benefit ratios estimated from the 
results of the current study.  When the cost-benefit ratios of having a pharmacist in 
such physician-pharmacists review team in helping to bring drug costs down was 
estimated, the cost-benefit ratio of having a pharmacist on board was valued to be 
5.85 based on savings in drug cost between the two groups. This positive ratio, 
coupled with the net annual return of S$34,909.20 in investing in one pharmacist to 
perform such tasks makes it worthwhile and justifiable to employ pharmacists to do 
such monitoring as their main duties. 
 
 In this study, due to other work commitments the pharmacists only spent about 
20% of their working hours monitoring patients’ drug regimes and counter-suggesting 
more optimal drug therapies. With lesser allocation of time to perform other tasks like 
distribution and dispensing of medications, as well as with better pharmacist-to-
patient ratio, there could be even more considerable drug costs savings for the patients. 
Indeed, when a conservative estimate of keeping the drug cost savings achieved 
annually as a constant, but varying the time spent by the pharmacist in monitoring 
patients’ drug therapies was done as per sensitivity analysis presented in the results 
section, the cost-benefit ratio attained was still maintained above 1. Actually, the 
probability that the cost-benefit ratios would dip below 1 as calculated by Monte 
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Carlo simulation was between 0.95 to 8% only, demonstrating that the intervention by 
pharmacists is more than likely to produce good return for investment for the 
healthcare system. Thus, other than just direct drug cost savings, this will also 
translate to drug costs savings for the government as most patients were receiving 
subsidized medications. Moreover in this study, improvement in the health related 
quality of life (HRQoL) as a result of the patients as a result of better management of 
their drug therapies was not studied. With a probable improvement in the HRQoL due 
to reduced DRPs, patients will benefit much more from such pharmaceutical care.  
 
 The sensitivity analysis based on the total hospital charge was not as 
extensively performed because the total hospital charge savings would not have been 
as reflective of the impact of the study as compared to the total drug cost savings. 
Total drug cost savings would be insightful of a direct impact as the interventions 
made by the pharmacists were mainly concerning DRPs and hence would have 
immediate effect on the drug costs. On the other hand, while such intervention might 
also impact the total hospital charge, it may be less pronounced as sometimes, 
laboratory tests and other procedures would be based on clinical pathways and 
treatment protocols which would not be immediately affected. Nevertheless, the 
sensitivity analysis carried out for the total hospital charge savings did show a 
favourable trend when there was the presence of a pharmacist in the review team. The 
results of the Monte Carlo simulation demonstrate that even when total hospital 
charge was concerned, the inclusion of a pharmacist was likely to result in positive 
return of investment with a probability of more than 70%. 
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 In conclusion, although the task of pharmacists in ensuring the safe and 
rational use of drugs in a managed care environment is not a new one, the findings 
from the current study supported the observations that the participation of pharmacists 
in physician-pharmacist review teams did demonstrate the potential quantum in 
reduction in drug costs, as well as has the possibility of improve the quality of life for 
in-patients. Another important finding from the current study is inferred from the 
relatively low number of interventions carried out by the pharmacists in the control 
group. Besides the reasons mentioned previously, it would also indicate that under the 
workload and arrangement of the current system, the pharmacists are left with very 
little time to carry out other functions besides those of dispensing and distribution. 
With such potential, hospital administrators should consider decreasing the 
pharmacist-to-patient ratio, as well as employing pharmacists to perform more 
pharmaceutical care roles to bring about better management of pharmacotherapy, 
result in more savings in drug costs, as well as to bring about better quality of life for 
the patients. 
 








Chapter 5  
Development of a New Algorithm  
to Identify the Causality of Adverse 
Drug Reactions 
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5.1 Introduction 
 To assess causality, differential diagnosis of adverse drug events can be 
achieved with the use of clinical judgments and/or algorithms.66 Both have their 
advantages and disadvantages. In practice, clinical judgment is usually the first step in 
the identification of any adverse drug event. However clinical judgment is not 
calibrated and the decision-making process is not explicit. Hence, it is neither 
transparent nor replicable,100 resulting in high levels of intra-rater and inter-rater 
disagreement.58, 101, 102 
 
 Algorithms, on the other hand, are either flow-charts or questionnaires that 
attempt to determine drug causation in the occurrence of an ADR by checking the 
temporal association between drug administration and the onset of the adverse drug 
event. The systematic approach in information acquisition helps to improve the 
reliability of assessments and increase inter- and intra-rater agreement.36, 58 Generally, 
the use of algorithms will provide more consistent results especially in the regulatory 
settings where the evaluator would not have the opportunity to observe the suspected 
ADR event first-hand. In the case of clinical settings, the use of an algorithm will 
augment clinical judgment. 
 
 Several algorithms for evaluating adverse drug events have been published.58-
62 These algorithms are used to assign a probability (e.g. definite, probable, possible, 
or unlikely) to an event thought to be an adverse drug event. However, several 
comparative studies had shown that different algorithms might sometimes disagree in 
the assigning of probability of risk to the same data set.103-105  
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 The incongruence of outcomes as reported may be explained by the different 
structure and approach used in these algorithms. The seven established ADR 
algorithms, namely, Karch’s,59 Kramer’s,60 Jones’,61 Naranjo’s,58 Bégaud’s,62 World 
Health Organization-Uppsala Monitoring Centre (WHO-UMC) causality assessment 
system106 and the guidelines used by the Adverse Drug Reaction Advisory Committee 
(ADRAC) in Australia107 which the current study would use for comparison can be 
broadly divided into three types: flow charts, tables and questionnaires. The 
advantages and disadvantages of these algorithms are summarized in Figure 5.1.  
 
 Some of the existing algorithms, e.g. Kramer’s, require too much information 
and are therefore more suited for academic research work rather than for clinical or 
regulatory use. Others have their own disadvantages that make them less user-friendly 
(Figure 5.1). Due to these reasons, there is a need to develop an algorithm to suit the 
needs of the Pharmacovigilance Unit in Singapore. Hence, in this study, the attempt 
was to develop a new ADR causality algorithm to incorporate the strengths of these 
existing ones, and yet well adapted for the use of clinicians and regulatory authorities 
without the need for extra clinical information than those already routinely collected. 
In other words, the present study intends to produce an ADR causality assignment 
algorithm that is “friendly” and practical for both clinicians and drug regulators. 
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Too time consuming 
May not have all the information 
Must know every answer 
Jones 
Pros 
Easy to use 
Cons 
Must know every answer 
Karch 
Pros 






Cover all the aspects to be checked 
for in 2 tables 
Cons 
Not intuitive. Can be difficult to use 
for evaluators who are not used to the 
tables. 
Compressed too much into 2 tables, 
can be confusing 
Naranjo 
Pros 
Easy to use 
No need to know all answers 
Cons 
Not every question is answerable 
ADRAC guidelines 
Pros 
Easy to use 




Cases may not be clear-cut 
WHO-UMC system 
Pros 
Good for detection of unknown 
and unexpected adverse reactions 
Cons 
Subjective 
May end up with a lot of probable 
and possible cases because of 
stringent criteria 
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5.2 Methods 
5.2.1 Development of the new algorithm 
 In developing the new algorithm, the ADR reporting form used by CDA when 
soliciting voluntary reports (Figure 5.2), were used as a basic platform to formulate 
the questions. This is to ensure that the questions for the new algorithm can be 
answered from the information routinely collected. With this approach, the resulting 
algorithm will be of practical use and impose minimal extra burden on information 
collection. The amount and types of information required in the form used by CDA is 
similar to those required by Medwatch (FDA)108 in USA and Therapeutic Goods 
Administration (TGA)109 in Australia. The information currently being collected 
include temporal effect between drug use and onset of ADR (derived from start date 
of suspected drug and date of onset of ADR); dose of suspected drug administered; 
objective evidences (e.g., laboratory results) contributing to confirm the adverse event; 
any similar reaction experienced by patients previously; effect upon stopping 
suspected drug; any re-challenge; any pre-existing or possibly new medical conditions 
that could have resulted in such an event; and any outstanding laboratory results to 
support the adverse event. 
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Figure 5.2 ADR reporting form used by CDA 
 
 
 From this platform, preliminary questions answerable from the ADR reporting 
form were derived. These questions were matched against the 56 questions used in 
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Kramer’s algorithm,60 the standard for comparison in our study because of the 
comprehensive nature of this algorithm. Those questions from Kramer’s algorithm 
which cannot be answered using information available on the ADR reporting form 
were eliminated. The remaining questions in Kramer’s algorithm were then 
summarized to form main questions and reconciled with the 9 initial questions to 
arrive at the modified questions for the new algorithm. 
 
 The scores were developed based on the importance of the various questions 
in determining if the suspected drug had indeed brought about the ADR. For each 
of the 8 questions, the options which contribute to the suspected drug being a 
causative agent for the ADR would receive a higher score compared to the options 
which did not support the drug as being the sole agent in bringing about the ADR. For 
more important questions (like temporal effect, presence of influence from existing 
clinical condition, use of antidotes and presence of re-challenge), the options which 
push the case towards positive association with the suspected drug will get higher 
weights compared to other, though important but not as crucial, questions. This is 
similar to the way Naranjo et al.58 described how the scoring system of their 
published algorithm was developed.  
 
 To determine the cut-off points for the different causality categories for the 
new algorithm, the distribution of theoretical “Unlikely”, “Possible”, “Probable” and 
“Definite” cases in Naranjo’s and Kramer’s algorithms were analyzed. These two 
algorithms were chosen because they share a similar answering format to the new 
algorithm under development, i.e., the questions required a ‘Yes’, ‘No’ or ‘Do Not 
Know’ type of answer. The researcher analysed the theoretical cases which can be 
 
Chapter 5: Development of a New ADR Algorithm 102
generated from these two algorithms and study the percentages of these theoretical 
cases which fall into these 4 separate categories and modeled against the same 
percentage range to develop the cut-off points for these 4 categories in the new 
algorithm.  
 
 The first step involved determination of the total number of possible case 
combinations for both algorithms. For Naranjo’s algorithm, there are ten questions 
and each question has three possible answers, giving a total number of 310 = 59,049 
case combinations. Kramer’s algorithm has a total of 56 questions, of which only 15 
questions would be needed to arrive at a causality for most suspected ADR cases. Of 
these 15 questions, two have three possible answers whilst the rest have two. Thus, 
the total number of case combinations is 32 x 213 = 73,728 cases. The “cut-off” scores 
of the two algorithms were then applied to their theoretical case combinations and the 
percentage of “Definite” cases in these two algorithms was found to be less than 2%, 
whereas the percentages of “Probable”, “Possible” and “Unlikely” cases range from 
7% to 26%, 54% to 61% and 17% to 32% of the total number of cases, respectively. 
Hence, an arbitrary cut-off of 1% of cases with the highest scores as “Definite”, the 
next 9% for “Probable”, and the following 60% for “Possible” and the last 30% as 
“Unlikely” were set and applied to the new algorithm. In the new algorithm, there are 
eight questions and each question has three possible answers. However, Questions 5 
and 6 in this algorithm are inter-related; if the answer to Question 5 is not unknown, 
the answer to Question 6 must be unknown to prevent logical contradiction. Likewise, 
if the answer to Question 6 is not unknown, the answer to Question 5 must be 
unknown. Thus the total number of possible case combinations for our algorithm is 38 
– (36 x 2 x 2) = 3645. To determine the appropriate cut-off for the definite case, the 
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scores from all the theoretical case combinations were analyzed and approximately 
1% of the cases (n=31) has a score of at least 12. Thus “12” was used as a cut-off in 
the new algorithm to differentiate between definite and probable cases. The other cut-
offs are found in a similar manner.  
 
5.2.2 Testing of the new algorithm 
 For testing the newly developed algorithm, anonymized ADR reports collected 
by the Pharmacovigilance Unit in the Centre for Drug Administration (CDA), Health 
Sciences Authority, Singapore were used. This unit in CDA is the national body in 
Singapore responsible for all pharmacovigilance and ADR monitoring activities. The 
anonymized ADR reports were voluntary reports consolidated from hospitals and 
clinics in Singapore during the period of January to August 2002. 
 
 To test the new algorithm, ADR causality score was first assigned to the 
usable cases by using the new algorithm together with seven different established 
algorithms – Kramer’s,60 Naranjo’s,58 Karch’s,59 Jones’,61 Bégaud’s,62 the guidelines 
used by the Adverse Drug Reaction Advisory Committee (ADRAC) in Australia107 
and the WHO-UMC causality assessment system.106 The results obtained from the 
various algorithms were translated into 4 categories of causality (Unlikely, Possible, 
Probable and Definite). ‘Unclassified’, ‘Unassessable’, and ‘Unclear’ categories in 
ADRAC guidelines were all re-grouped under the ‘Unlikely’ category for ease of 
comparison. These resulting categories from each algorithm were matched against the 
outcomes obtained with Kramer’s algorithm,60 the “gold” standard in this study to 
compare the relative performance of all the algorithms. To avoid inter-rater variation, 
only one of the investigators was involved in testing the algorithms. Any need for 
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confirmation of decisions was resolved with the other investigators. The clinical 
evaluators at the Pharmacovigilance Unit in the Centre for Drug Administration, 
Health Sciences Authority, Singapore were approached for their expert opinions 
whenever necessary. 
 
 For all these comparisons, the percentages of congruency between the 
algorithms were then calculated. The 95% confidence intervals were obtained using 
exact binomial calculations. 
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5.3 Results 
 Using information available from the ADR reporting form used locally by 
CDA, 9 potential questions were derived for the new ADR algorithm (Table 5.1). 
After matching these questions with the 56 questions in Kramer’s algorithm, the new 
algorithm was consolidated with a set of 8 questions and the scores for their possible 
options as present in Table 5.2. In the final version, the question regarding the 
presence of laboratory tests results was removed because this information is seldom 
reported in spontaneous ADR reporting forms. 
 
Table 5.1 List of “answerable” questions 
 Questions 
1 Any temporal effect between drug and ADR? 
2 Suspected drug known to have this effect? 
3 Appropriate dosage (for general population) was used? 
4 Reaction confirmed by objective evidence? 
5 Improvement upon de-challenge? 
6 Patient had such reaction before? 
7 Any re-challenge? 
8 Present medical condition or other medical condition may have given rise to 
this reaction? 
9 Any outstanding laboratory test results? 
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Table 5.2 List of questions with scores for our new ADR algorithm 




1 Is there a reasonable time interval 
between administration of the 
suspected drug and the adverse 
reaction? 
2 -4 0 - 
2 Has the adverse reaction been 
associated with the suspected drug 
before? 
2 -2 0 - 
3 Could this adverse reaction be due to 
an existing clinical condition? 
0 4 0 - 
4 Is there any over-dose of the 
suspected drug? 
2 0 0 - 
5 If the drug was discontinued, did the 
adverse reaction improve? (if the 
drug brought about irreversible 
changes, please classify as “Do Not 
Know”) 
1 -2 0 0 
6 If the drug was NOT discontinued, 
did the reaction resolved on its own? 
-2 0 0 0 
7 Did the reaction improve when 
specific antagonist/antidote was 
administered? 
4 0 1 0 
8 Did the adverse reaction recur when 
the suspected drug was discontinued 
and re-administered again? 
4 -2 0 0 
 Total score:     
 
 The final cut-offs for the categories can be seen in Table 5.3. This new 
algorithm was then tested with the data set from CDA as described. 
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 During the study period of January to August 2002, there were 518 ADR 
reports collected by the Pharmacovigilance Unit at CDA. Of these, 68 reports were 
not usable (including 18 reports not related to ADR; 11 reports due to complementary 
medicines which were not intended to be used for developing our new algorithm; 39 
reports with missing essential information). The remaining 450 usable cases were 
used for the testing of our newly developed algorithm, as well as for the comparative 
study with the established algorithms. 
 
 The seven established algorithms mentioned were applied to the 450 usable 
cases. The assigned causalities were all translated into four different categories which 
were then compared against that obtained with Kramer’s algorithm. Results from this 
comparison are shown in Table 5.4 (for absolute number of cases in the different 
causality classification) and Table 5.5 (for percentage of congruency with Kramer’s 
algorithm). The comparison of percentage of congruency between the different 
algorithms is presented in Table 5.6. 
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Table 5.4 A comparison of the different causality classification of the 450 ADR 
reports 
Algorithm Definite Probable Possible Unlikely Unclassifiable
Kramer 12 370 64 4 0 
Our new algorithm 13 367 70 0 0 
ADRAC 4 436 10 0 0 
Jones 0 248 21 0 181 
Karch 4 236 1 35 174 
Naranjo 4 391 54 1 0 
WHO-UMC 3 196 175 1 75 
Bégaud 4 226 165 55 0 
 
Table 5.5 Results from comparative study of the various algorithms against 
Kramer’s 
Algorithm % of Congruency 95% CI 
Our new algorithm 98.44 96.82 – 99.37 
Naranjo 94.67 92.17 – 96.55 
ADRAC 84.44 80.76 – 87.67 
Jones 56.44 51.72 – 61.08 
Bégaud 55.33 50.61 – 59.99 
Karch 52.22 47.49 – 56.92 
WHO-UMC 45.11 40.45 – 49.84 
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algorithm Naranjo ADRAC Jones Bégaud Karch 
WHO-
UMC 
Kramer 100.00 98.44 94.67 84.44 56.44 55.33 52.22 45.11 
New algorithm 98.44 100.00 94.44 84.67 56.44 54.44 51.11 44.89 
Naranjo 94.67 94.44 100.00 89.78 57.11 55.11 53.56 45.11 
ADRAC 84.44 84.67 89.78 100.00 54.89 51.56 53.33 44.22 
Jones 56.44 56.44 57.11 54.89 100.00 52.89 88.89 53.33 
Bégaud 55.33 54.44 55.11 51.56 52.89 100.00 57.11 70.44 
Karch 52.22 51.11 53.56 53.33 88.89 57.11 100.00 52.00 
WHO-UMC 45.11 44.89 45.11 44.22 53.33 70.44 52.00 100.00 
 
 Of the established algorithms, Naranjo’s showed the highest percentage of 
congruency (94.67%) as compared to Kramer’s. This is then followed by guidelines 
used by ADRAC (84.44%), Jones’ (56.44%), Bégaud’s (55.33%), Karch’s (52.22%) 
and WHO-UMC causality assessment system (45.11%) in descending order. The 
results obtained with the new algorithm was 98.44% (95% CI: 96.82 – 99.37) 
congruent to the results from Kramer’s algorithm. 
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5.4 Discussion 
 In the process of developing a new ADR algorithm, first and foremost, the 
format had to be decided upon. It was decided against flow-chart or table format 
because once the evaluator could not answer any questions in these formats, they 
would find it almost impossible to proceed further with the algorithm to arrive at the 
final ADR causality of the suspected drug. Where guidelines or assessment criteria 
were concerned, the researchers were not in favor of using that as a format for the 
new algorithm due to presence of evidence that using such guidelines were neither 
reproducible, valid nor accountable.100 
 
 After the formulation of the questions, the scoring system similar to that used 
by Naranjo et al.58 was adopted. The rationale being that the user can just answer each 
question in the algorithm to the best of his or her ability and sum up the score for all 
the questions. This total score will then be translated into causality categories. 
However, Naranjo’s algorithm could not be used without modifications because of the 
presence of questions like whether the reaction appeared when a placebo was 
administered, or if there was any increase in severity of the reaction when the drug 
dose was increased and any decrease in severity when the drug dose was decreased. 
Most of the time, it is impossible to answer these questions because it is not a 
common practice to use placebos clinically. In addition, in the case of a likely ADR, 
the suspected drug most likely would have been discontinued pending further 
investigation, instead of an upward or downward adjustment of the drug doses. The 
perpetual answer of “Do Not Know” to these two questions will tend to lower the 
total score obtained for a suspected drug hence affecting an accurate final causality 
assignment. Upon checking the ADR reporting forms by Medwatch108 and 
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ADRAC,109 it was found that information required to answer these questions are also 
not solicited in these forms. Hence, these 2 questions may be seen as redundant in 
present day clinical context and may not be necessary in an ADR algorithm. 
 
 Hence, to minimize the problem of having unanswerable questions most of the 
time, the approach used in the current study was to derive a set of “answerable” 
questions first. Based on the information usually collected from ADR reporting forms 
and comparison with the questions from Kramer’s algorithm, the final set of eight 
questions was obtained. Although this is only two questions lesser than Naranjo’s 
algorithm, the questions are more answerable based on the information available 
when an ADR report is made. This new algorithm was then subjected to testing and 
comparison study. 
  
 In this study, the percentage of congruency, that is, the percentage of cases 
which had exactly the same causality assignments, was used to evaluate the 
comparative performance of all the algorithms against Kramer’s algorithm. From the 
results obtained, it can be seen that compared with the other six established algorithms, 
Naranjo’s algorithm showed the most agreement with Kramer’s, followed by 
ADRAC’s, Jones’, Bégaud’s, Karch’s and WHO-UMC’s in descending order. On the 
other hand, the results obtained using the new algorithm managed to reach 98.44% 
congruency with Kramer’s algorithm.  
 
 The relatively poor performance of several established algorithms such as 
Jones’, Karch’s and WHO-UMC’s algorithm was due to the presence of substantial 
unclassifiable cases, ranging from 16.7% (WHO-UMC) to 40.2% (Jones’). Hence, 
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these three algorithms are not particularly suited for clinical use based on the type of 
information from our ADR reports. In addition, WHO-UMC’s algorithm assigned 163 
cases as ‘Possible’ instead of ‘Probable’ causality like Kramer’s (See Table 5.7), 
contributing further to its low congruency with Kramer’s algorithm. 
 
 
Chapter 5: Development of a New ADR Algorithm 113
Table 5.7 Actual number of ADR cases with the same causality assignment as 
that by Kramer’s algorithm 
Kramer’s algorithm  
Definite Probable Possible Unlikely 
Definite  12 1 0 0 
Probable  0 367 0 0 









Unlikely  0 0 0 0 
Definite  4 0 0 0 
Probable  8 370 13 0 






Unlikely  0 0 0 1 
Definite  4 0 0 0 
Probable  8 370 58 0 












Unlikely  0 0 0 0 
Definite  4 0 0 0 
Probable  8 218 0 0 




Unlikely  0 10 41 4 
Definite  4 0 0 0 
Probable  8 228 0 0 
Possible  0 1 0 0 





Definite  0 0 0 0 
Probable  12 236 0 0 
Possible  0 2 18 1 





Definite  3 0 0 0 
Probable  7 189 0 0 
Possible  1 163 11 0 
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 As mentioned above, compared with other established algorithms, the new 
algorithm managed to achieve a higher congruency with Kramer’s algorithm 
(98.44%). Although it may be argued that this would be expected as this only 
demonstrates the conceptual equivalence between the two algorithms, the high level 
of congruency does show that the new “short” algorithm can achieve quite respectable 
results as a very comprehensive one. Another pertinent question to ask at this juncture 
would be: “What if both Kramer’s and the new algorithms were both wrong?” The 
answer to this question can be found by examining the numbers of definite cases 
assigned by the various algorithms (Table 5.4). In pharmacovigilance, the ability to 
identify “definite ADR cases” is of paramount importance. The comparative results 
showed that the new algorithm and Kramer’s algorithm have lower threshold than 
other algorithms in triggering off warning signals, i.e. in assigning of “definite” cases. 
The lower threshold represents a more conservative approach that would be 
acceptable in the context of public safety. Hence, with this short algorithm, it was felt 
that it provides ease of use and requires lesser time to get a causality assignment for 
the suspected drug. Although patient-unrelated factors such as the quality of data 
documentation and the medical knowledge of the assessors are likely to influence the 
assessment outcomes, the presence of such an algorithm is nevertheless still valuable 
for improving the ADR reports by focusing on pertinent information, particularly the 
dates concerning drugs and events. On the whole, this will be useful from both 
clinical practices as well as from drug-regulation perspectives. Even though this new 
ADR drug causality assessment is developed to cater for local needs, there is no 
reason why it could not be used in other regions which are looking for a simple and 
easy method to assign ADR causality.  
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 Having developed the basic algorithm, more time needs to be spent in 
improving on the questions to ensure ease of understanding and to make sure that 
there is minimal ambiguity for the person using the algorithm. The scoring system can 
be further refined so as to increase the sensitivity of this algorithm scale. 
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5.5 Conclusion 
 By evaluating the advantages and disadvantages of several established 
algorithms for assigning ADR causality, a simple algorithm that requires no extra data 
collection than those routinely collected in most ADR reporting forms have been 
developed. In terms of performance, the new “short” algorithm can achieve similar 
result with a much more comprehensive algorithm. In addition, the algorithm adopts a 
lower threshold in assigning “definite” ADR cases than most established algorithms, a 
feature that may be desirable in the context of public safety. In conclusion, a short 
algorithm that provides ease of use and is less demanding on time required in getting 
a causality assignment for a suspected drug has been developed. This algorithm would 
provide clinicians and drug regulators with a handy tool to assign ADR causality. 
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6.1 Introduction 
 The detrimental effects of adverse drug reactions (ADRs) contributing to 
major problems like morbidity, mortality and high cost of patient care have been well 
established.8, 50, 101 In order to effectively manage and minimize ADRs, it is necessary 
to have more precise and accurate assessment of the causality of the ADRs as well as 
predictors for likely occurrence of ADRs. In the former case, the challenge lies in 
determining the probability that the suspected drug is the actual cause of the ADR. 
 
 To date, spontaneous adverse drug reactions’ reporting is the backbone of 
most pharmacovigilance centres,35, 110 medical institutions and clinical trials.111 These 
spontaneous reports will give rise to signals which alert the regulatory authorities or 
the physicians about the dangers posed by the suspected drugs involved. The major 
problem encountered here is the differentiation between “signals” and “noise”. 
Studies have been done to evaluate the impact of these signals detected from 
spontaneous ADR reporting data.56 Generally speaking, such signals will be useful 
and be less problematic for national pharmacovigilance units that collect huge amount 
of spontaneous ADR reporting and hence have a large database of ADR reports to 
determine the significance of the signals. However, for countries with smaller 
population and hence lesser spontaneous reports, or medical institutions and 
pharmaceutical companies conducting clinical trials on yet to be marketed drugs, this 
method may not be the most ideal. Furthermore, for impact analysis of signals 
detected from spontaneous ADR reporting described by Waller et al.,56 the scoring for 
strengths and weaknesses of the evidence (which is the drug causality of the ADR) is 
said as based on judgment of the overall quality of the series of case reports received. 
This would still lead to the problem of inter- and intra-rater disagreement on causality 
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since there is substantial subjective element in the judgment process. Hence, it is of 
importance to develop a system capable of assessing the spontaneous reports that is 
not only more objective but at the same instance able to predict the likelihood that a 
signal is a true signal. In other words, it should possess the same properties as a good 
screening test. 
 
 In the current practice of assessing any suspected ADRs, drug causality can be 
determined by using either clinical judgments or algorithms.66 Although always the 
first and unavoidable essential step in ADR detection and assessment, clinical 
judgments often have low inter- and intra-rater agreements because of implicit 
decision-making process.58, 101, 102 Algorithms on the other hand, are structured 
operational systems for the identification of ADRs. Hence theoretically, using 
algorithms to evaluate the causality of ADRs make the evaluation less arbitrary, more 
objective and also produces higher inter- and intra-rater agreements.58 
 
 Several algorithms have been developed in the late 1970s and early 80s. For 
these algorithms, weights were arbitrarily assigned to the various criteria in 
questionnaires based on their perceived importance, and validity of the algorithms 
was checked based on the degree of agreement between the algorithm-derived results 
and experts’ opinions. Although giving arbitrary weights to criteria is a qualitative 
way of determining the causality of an ADR and a good guide for assigning causality, 
this qualitative nature also means that it is not possible to determine the probability 
(or likelihood) of the ADR causality based on the results obtained.  
 
 
Chapter 6: Designing a Probability Scoring System for ADR Assessment 120
 To help overcome the above problems, a robust yet easy to use ADR 
algorithm that could offer a more objective way to determine ADR causality as well 
as the probability of the causal relationship should be developed. With a probability 
score, when the algorithm is applied to a suspected ADR situation, it gives a 
quantitative likelihood of the ADR being caused by the suspected drug. This will 
allow a quantification of ADR signals for small pharmacovigilance centres without 
large databases. At the same time, it will also be extremely useful for application in 
clinical practice, as well as in clinical trials for new drugs where there may be 
unprecedented ADRs. For large national pharmacovigilance centres, a quantitative 
ADR algorithm can be incorporated into their current system to get an even more 
accurate impact analysis of their ADR data from spontaneous reporting.52, 56 
 
 Nevertheless, the new algorithm should not be designed just purely for 
academic purpose but attain a level of balance between scientific rigor and at the same 
time, simple enough for use in clinical or regulatory setting. Henceforth, the criteria 
used by the algorithm in assessing the probability that an ADR is caused by the 
suspected drug should be determinable based on routinely collected data. On top of 
that, like any other scientific measuring instruments, high reproducibility and validity 
are also essential attributes for a good ADR algorithm.  
 
 Currently, Bayesian Adverse Reaction Diagnostic Instrument (BARDI), is an 
algorithm which is able to determine the probability of ADR causality.112 BARDI 
calculates the probability of ADR causality using six components: (1) prior odds, 
which is the ratio of the drug-attributable risk and non drug-attributable risk based on 
epidemiologic information, and (2) five likelihood ratios, which are (a) patient history, 
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(b) timing of ADR with respect to drug administration, (c) characteristics of the ADR, 
(d) drug de-challenge and (e) drug re-challenge. A major advantage of BARDI is its 
ability to incorporate any new information regarding the drug, patient or ADR into the 
probability assessment of the ADR causality. However, this is time-consuming and 
there are considerable difficulties in determining the prior odds ratio and likelihood 
ratios. Hence, there is a need to develop an algorithm that has the pros of both ease of 
use and ability to give a probability of the ADR causality.  
 
Table 6.1 The eight criteria used in our algorithm 
1 Is there a reasonable time interval between administration of the suspected 
drug and the adverse reaction? 
2 Has the adverse reaction been associated with the suspected drug before? 
3 Could this adverse reaction be due to an existing clinical condition? 
4 Is there any over-dose of the suspected drug? 
5 If the drug was discontinued, did the adverse reaction improve? (if the drug 
brought about irreversible changes, please classify as “Do Not Know”) 
6 If the drug was NOT discontinued, did the reaction resolved on its own? 
7 Did the reaction improve when specific antagonist/antidote was administered? 
8 Did the adverse reaction recur when the suspected drug was discontinued and 
re-administered again? 
 
 In the previous chapter, the development of a new algorithm with 8 criteria for 
assigning ADR causality with the purpose of balancing scientific rigor and 
applicability has been reported (Table 6.1). The preliminary results showed that the 
new algorithm can perform better in detecting and assigning causality of ADRs 
compared with several well established algorithms.113 Using the insights on the 
limitation of qualitative approach in assigning weightage, the scoring system of the 
algorithm has been further improved using the genetic algorithm approach so that the 
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final score can also be used as a measure of the probability of ADR causality. Genetic 
algorithm is a form of artificial intelligence and its use in the medical field has been 
published.68-71 This chapter reports the developmental process and the performance of 
the improved algorithm. 
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6.2 Methods 
6.2.1 Development of the scoring system 
 The intention was to identify several ADR cases with known ADR causality 
probability values as reference points for the development and testing of the scoring 
system. However, it would be too time-consuming to establish a scoring system that 
satisfy all these reference points through an exhaustive search of all possible scoring 
systems by systematically varying all the scores in the scoring system. Thus genetic 
algorithm was used to find a suitable scoring system.  
 
 Theoretically, the new scoring system should assign a higher probability to 
‘Definite’ ADR cases than other causality categories. With this, seven rules (Table 6.2) 
which define all possible combinations of ‘Definite’ ADR cases were identified. By 
identifying all possible combinations of ‘Definite’ ADR cases, it will be possible to 
test the new scoring system to determine whether it satisfies this condition. The seven 
rules were identified based on a review of cases where the suspected drugs were 
considered to have definite causality effect in the reported ADRs. These cases were 
picked out based on retrospective inspection of all the ADR reports by a panel of 
experts from the regulatory body Centre for Drug Administration, CDA (the FDA 
equivalent in Singapore).  
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Table 6.2 Rules that define ‘Definite’ cases 
Rule Criteria to fulfil for each rule 
1 - Presence of temporal effect 
- ADR improve with de-challenge and recur with re-challenge 
- No antidote/antagonist is given 
 
2 - Present of temporal effect 
- ADR responds to antidote/antagonist administered 
- If a re-challenge is performed, result must not be negative 
 
3 - Presence of temporal effect 
- Not due to any existing clinical condition 
- Presence of drug overdose which improve upon de-challenge 
- If a re-challenge is performed, result must not be negative 
 
4 - Presence of temporal effect 
- ADR has been associated with the suspected drug before 
- Not due to any existing clinical condition 
- Improvement of ADR upon de-challenge 
- If a re-challenge is performed, result must not be negative 
 
5 - Presence of temporal effect 
- ADR recur on re-challenge 
- ADR may or may not improve when antidote/antagonist is 
administered 
(This rule cover for ADR resulting from excipients used in the formulation 
of the drug) 
 
6 - Unknown temporal status 
- ADR respond to antidote/antagonist 
- ADR recur upon re-challenge 
 
7 - Unknown temporal status 
- Not due to any existing clinical condition 
- ADR improve with de-challenge 
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Table 6.3 Rules that define ‘Probable’ cases 
Rule Criteria to fulfil for each rule 
1 - Unknown temporal status 
- Existing clinical condition 
- ADR improve with de-challenge and recur with re-challenge 
- No antidote/antagonist is given 
 
2 - Unknown temporal status 
- ADR responds to antidote/antagonist administered 
- If a re-challenge is performed, result is unknown 
 
3 - Unknown temporal status 
- Not due to any existing clinical condition 
- Presence of drug overdose which improve upon de-challenge 
- If a re-challenge is performed, result is unknown 
 
4 - Unknown temporal status 
- ADR has been associated with the suspected drug before 
- Not due to any existing clinical condition 
- Improvement of ADR upon de-challenge 
- If a re-challenge is performed, result is unknown 
 
5 - Unknown temporal status 
- ADR recur on re-challenge 
- ADR does not improve when antidote/antagonist is administered 
 
6 - Presence of temporal effect 
- Not due to any existing clinical condition 
- Presence of drug overdose 
- Effect of de-challenge is unknown 
- No antidote/antagonist given 
- No re-challenge 
 
7 - Presence of temporal effect 
- ADR has been associated with the suspected drug before 
- Not due to any existing clinical condition 
- Effect of de-challenge is unknown 
- No antidote/antagonist given 
- No re-challenge 
 
 
 Although it will be useful to have a set of similar rules to define ‘Probable’, 
‘Possible’ and ‘Unlikely’ ADR cases, it is difficult to classify all the remaining ADR 
cases into these three categories. Thus, only some rules which defined some 
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combinations of ‘Probable’ ADR cases were identified (Table 6.3). These rules were 
identified by slight modification of the rules for ‘Definite’ ADR cases. For example, 
if a rule for ‘Definite’ ADR cases contains a criterion which implicate the drug as a 
causative agent (Rule 2 in Table 6.2), changing that criterion to a ‘Unknown’ or ‘Not 
Applicable’ option will change the rule from defining ‘Definite’ ADR cases to 
defining ‘Probable’ ADR cases (Rule 2 in Table 6.3).  
 
Table 6.4 ADR cases with known probability values 
Rule Criteria to fulfil for each rule Probability
1 - Presence of temporal effect 
- ADR has been associated with the suspected drug 
before 
- Not due to any existing clinical condition 
- Presence of drug overdose 
- ADR respond to antidote/antagonist 
- ADR recur upon re-challenge 
 
1 
2 - Unknown temporal status 
- ADR may not have been associated with the suspected 
drug before 
- Unknown existing clinical condition 
- Unknown drug dose 
- Effect of de-challenge is unknown 
- If antidote/antagonist given, effect is unknown 
- If a re-challenge is performed, result is unknown 
 
0.5 
3 - No temporal effect 
- ADR has not been associated with the suspected drug 
before 
- Existing clinical condition 
- No drug overdose 
- Effect of de-challenge is unknown 




 In addition to identification of rules for ‘Definite’ and ‘Probable’ ADR cases, 
several ADR cases with known probability values were also identified (Table 6.4). 
The known probability values are 1, which corresponds to ADR cases where all the 
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criteria implicate the drug as a causative agent, 0.5, which corresponds to ADR cases 
where all the criteria are either ‘Unknown’ or ‘Not Applicable’ options, and 0, which 
corresponds to ADR cases where all the criteria exclude the drug of any possible 
causal effect.  
 
 The scores in the new scoring system were determined with the help of genetic 
algorithm67 which is shown schematically in Figure 6.1. It comprises of four phases: 
initialization, evaluation, exploitation and exploration. The initialization phase 
involves constructing an initial population of scoring systems. Typically, the 
population size used in genetic algorithms is in the range of 50 to 500. In our study, 
we tentatively used an initial population of 300 randomly generated scoring systems. 
 
 During the evaluation phase, each scoring system is evaluated by calculating 
its fitness score. The fitness score indicates how well a scoring system satisfies all the 
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where NTdef is the total number of ‘Definite’ ADR cases defined by the rules in Table 
6.2, NFdef is the total number of ‘Not definite’ ADR cases which have higher or 
equivalent total score as ‘Definite’ ADR cases. NTpro is the total number of ‘Probable’ 
ADR cases defined by the rules in Table 6.3, NFpro is the total number of these 
‘Probable’ ADR cases which have a probability value below 0.5. NP1, NP0.5, and NP0 
are the total number of cases which should have an ADR probability of 1, 0.5 and 0 
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respectively and NTP1, NTP0.5, and NTP0 are the actual number of these cases that have 
these probabilities. Thus a scoring system that satisfy all the reference points will 
have a fitness score of 5 and if one is found, then further processes are stopped and 
the scoring system will be validated to ensure it is useful. Otherwise, the genetic 
algorithm proceeds to the exploitation phase. 
 
Figure 6.1 Schematic diagram of how genetic algorithm works  
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 In the exploitation phase, the scoring systems are ranked in terms of their 
fitness score and higher ranked scoring systems are selected more frequently to 
replace the bottom 90% of the current population. This method was used because the 
basic assumption in genetic algorithm is that scoring systems with higher fitness 
scores will have higher probability of producing scoring systems with even higher 
fitness scores, leading eventually to scoring systems which have the desired fitness 
scores. The exploitation phase helps to increase the average fitness scores of the 
population as multiple copies of high ranking scoring systems are more likely to be 
retained. However, this will also reduce the diversity of the population. This problem 
will be solved by the exploration phase. 
 
 The last phase of genetic algorithm, exploration, is used to introduce variation 
into the new population. Recombination and mutation are two events that occur 
during exploration. In recombination, two different scoring systems exchange some of 
their scores with each other. This creates two new scoring systems and may result in 
major improvement in fitness if the right fractions are joined together. During 
mutation, individual scores in the scoring systems may change to another randomly 
selected value. The role of mutation is to maintain diversity in the population by 
ensuring different scores have equal chance to be included in a scoring systems. Since 
recombination and mutation are random processes, there is a slight possibility that 
scoring systems with high fitness scores may change to new scoring systems with 
lower fitness scores as a result of the exploration phase. Thus the top 10% of the 
population are not subjected to the recombination and mutation process in order to 
ensure that scoring systems with high fitness scores are not removed accidentally. 
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After the exploration phase, the genetic algorithm returns to the evaluation phase and 
the cycle repeats until the desired scoring system is found.  
 
 Once the new scoring system has been established, the probability of ADR 





−= −  
where S is the total score of the ADR case, Smin and Smax is the minimum and 
maximum possible score of the scoring system respectively (Table 6.5). 
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Table 6.5 New scoring system for the algorithm 
  Yes No Do Not Know 
Not 
Applicable 
1 Is there a reasonable time interval 
between administration of the 
suspected drug and the adverse 
reaction? 
 
49 0 36 - 
2 Has the adverse reaction been 
associated with the suspected drug 
before? 
 
1 0 0 - 
3 Could this adverse reaction be due to 
an existing clinical condition? 
 
0 7 1 - 
4 Is there any over-dose of the 
suspected drug? 
 
2 0 0 - 
5 When the drug was discontinued, did 
the adverse reaction improve within a 
reasonable period of time? 
 
14 0 7 7 
6 When the drug was NOT 
discontinued, did the reaction 
resolved on its own? 
 
0 1 0 0 
7 Did the reaction improve when 
specific antagonist/antidote towards 
the suspected drug was administered? 
 
17 0 1 1 
8 Did the adverse reaction recur when 
the suspected drug was discontinued 
and re-administered? 
 
33 0 17 17 
 Total score, S: 
 
    
 Probability, P = (S - 8) / 108:  
 
    
Causality categories 
Definite: 0.75 ≤ P ≤ 1 (S ≥ 89) 
Probable: 0.63 ≤ P < 0.75 (76 ≤ S ≤ 88) 
Possible: 0.50 ≤ P < 0.63 (62 ≤ S ≤ 75) 
 Unlikely: 0 ≤ P < 0.50 (S ≤ 61) 
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6.2.2 Testing of new scoring system 
 In order to test the ability of this newly derived scoring system to assign 
causality probability, 4 different ADR cases, with varying amount of information 
available, were selected from the pool of ADR reports (see Chapter 5). The 
description of these 4 cases can be seen in Table 6.6. The probability value derived 
after subjecting each case through the new scoring system should tell us the likelihood 
that the ADR is caused by the suspected drug. 
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Table 6.6 ADR cases with varying amount of information available 
ADR case 1 
A 19 year old female presented with scattered macular discrete red rashes 1 day 
after a lignocaine gel was applied to her buccal cavity prior to a tooth extraction. 
Patient had not recovered from the rash 5 days after the initial onset. It is not known 
if the patient was taking any other medications concurrently or if she has history of 
drug allergy. 
 
Causality assessment for lignocaine  
Total score, S = 0 + 1 + 7 + 0 + 7 + 0 + 1 + 17 = 33 
Probability of causing ADR = (33-8)/108 = 0.231 
ADR case 2 
A 30 year old female patient, with no known drug allergy, presented with alopecia 
areata a few days after taking a single dose of fluconazole 150mg for the treatment 
of vaginal candidasis. Patient recovered from the condition 1 month after the single 
dose ingestion. 
 
Causality assessment for fluconazole 
Total score, S = 36 + 1 + 7 + 0 + 7 + 0 + 1 + 17 = 69 
Probability of causing ADR = (69-8)/108 = 0.565 
ADR case 3 
A 61 year old male patient was prescribed naproxen 275mg per oral for treatment of 
toothache. Following the first dose of naproxen, he developed peri-orbital swelling, 
wheezing and hoarseness of voice. IV hydrocortisone and nebulisation were given 
to treat his wheezing and patient recovered. Patient had previous allergies with 
paracetamol and phenylbutazone. 
 
Causality assessment for naproxen 
Total score, S = 49 + 0 + 7 + 0 + 14 + 0 + 1 + 17 = 88 
Probability of causing ADR = (88-8)/108 = 0.741 
ADR case 4 
A female patient who has been taking rofecoxib for 6 months for the treatment of 
knee osteoarthritis experienced low platelet count. Platelet count returned to normal 
following a de-challenge, but decreased again when therapy was re-introduced. 
Therapy with rofecoxib was subsequently discontinued. The patient had a medical 
history of stroke and has the following concurrent medical conditions: atrial 
fibrillation, dementia, ischaemic heart disease. 
 
Causality assessment for rofecoxib 
Total score, S = 49 + 1 + 7 + 0 + 14 + 0 + 1 + 33 = 105 
Probability of causing ADR = (105-8)/108 = 0.898 
 
 Although the aim is to produce a scoring system which provides ADR 
probability rather than a qualitative causality assessment, it is still important to make 
sure that the algorithm developed in this work is able to perform at least as well as 
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previously published algorithms in determining the causality of the suspected drug. 
However, a direct comparison is not possible since previous algorithms give 
categories of causality while the present algorithm gives only a probability value. 
Thus probability cut-off values need to be established to convert probability values to 
causality categories so that comparison with previous algorithms can be made. The 
probability cut-off values to differentiate between ‘Definite’ and ‘Probable’ ADR 
cases and between ‘Probable’ and ‘Possible’ ADR cases can be obtained by analyzing 
the probability values of the ‘Definite’ and ‘Probable’ ADR cases which have been 
identified in Tables 6.2 and 6.3. A probability cut-off value of 0.5 is used as a lower 
limit for ‘Possible’ ADR cases as it corresponds to a situation where there is no 
information available to implicate or exclude the drug of any possible causal effect. 
 
 Testing of the algorithm with this new scoring system was performed on 37 
‘Definite’ ADR cases. These 37 cases were taken from a total pool of 468 ADR 
reports received by the Pharmacovigilance Unit in CDA during the period of 
September 2002 and March 2003. As mentioned in the previous chapter, this unit is 
the national body in Singapore managing ADR monitoring. The ADR cases were 
classified as ‘Definite’ cases based on retrospective inspection of all the ADR reports 
by experts from CDA. These cases were classical ones which displayed positive 
temporal effects, and they were known adverse effects of the offending drugs 
involved. This test would enable a determination on how rigorous the new algorithm 
is in picking out ‘Definite’ ADRs resulted from the suspected drugs. Concurrently, 
seven other algorithms (namely, Naranjo,58 Kramer,60 Karch,59 Jones,61 Bégaud,62 
ADRAC’s guidelines107 and WHO-UMC causality assessment106) were applied to 
these 37 ‘Definite’ ADR cases to help assess how the new algorithm compare to these 
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existing ones in terms of percentage accuracy in picking out these similar ‘Definite’ 
cases. 
 
6.2.3 Developing of appendix for existing algorithm 
 An appendix is included in the algorithm to help increase inter-rater agreement. 
This appendix aims to clarify the meaning of the criteria so that the amount of 
ambiguity when applying the algorithm will be very much reduced. To test the 
effectiveness of this appendix, 3 evaluators (all qualified pharmacists with experience 
in clinical settings) were asked to apply the algorithm to evaluate 50 randomly 
selected ADR reports, first without the appendix and then re-evaluated the same cases 
3 months later with the appendix. This three-month lag was to ensure that the 
evaluators have forgotten their previous experience with the cases.  
 
 For each rater, the percentage difference for each criterion between the 
absence and presence of the appendix was calculated. A high percentage difference 
would support that the appendix did create an impact in the way the rater graded the 
criterion. However, we have to check whether this difference translates to an actual 
increase in the inter-rater agreement or have no impact on it. This inter-rater 
agreement will be tested using Kappa statistics using SPSS Version 12.0.114 
 
 To test the content validity of our algorithm, we carried out a sensitivity and 
specificity analysis. A similar analysis was performed using the guidelines adopted by 
ADRAC. These analyses would allow a comparison of performance between our 
algorithm and an existing algorithm. 
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6.3 Results 
 The optimum scores for each of the possible answers for the 8 criteria derived 
for the algorithm are shown in Table 6.5. Probability cut-off values of 0.75 and 0.63 
were found to be differentiating between ‘Definite’ and ‘Probable’ ADR cases and 
between ‘Probable’ and ‘Possible’ ADR cases respectively. These probability cut-off 
values correspond to total scores of 89 and 76 respectively. The probability cut-off 
value for classifying ‘Possible’ and ‘Unlikely’ ADR cases was fixed at 0.5 and this 
correspond to a total score of 62.  
 
 The results obtained from the 4 different cases (Table 6.6) showed that this 
new scoring system is able to differentiate the ADR probabilities based on the 
information provided in standard ADR reporting forms. A probability of 0.231 in 
Case 1 showed that the adverse reaction presented in the patient presented is most 
likely not to be due to the drug thought to be involved. On the other hand, a 
probability score of 0.898 in Case 4 showed that there is very high likelihood that 
rofecoxib is the offending agent which resulted in the episodes of thrombocytopenia 
in the patient. 
 
 When this new version of the algorithm was applied to the 468 ADR reports 
from CDA, of which 37 reports had ‘Definite’ causality, 83.8% of the 37 cases were 
identified as ‘Definite’ by the algorithm, and the specificity of the new algorithm was 




Chapter 6: Designing a Probability Scoring System for ADR Assessment 137
Table 6.7 Sensitivity and specificity comparison of various existing algorithms 
Algorithms Sensitivity (%) Specificity (%) 
New algorithm 83.78 71.00 
Naranjo 16.22 98.84 
Kramer 8.11 99.30 
Karch 16.22 99.07 
Jones 0 100.00 
Bégaud 5.41 100.00 
ADRAC 21.62 98.38 
WHO-UMC 2.70 99.07 
 
 The newly added appendix for the algorithm is shown in Table 6.8. The results 
obtained from comparing the difference in individual criterion between the algorithm 
with and without the appendix can be seen in Table 6.9. Fifty cases were evaluated by 
each of the three rater and the results showed that Criterion 2, followed by 3, 4 and 5 
displayed the most changes in descending order.  
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Table 6.8 Appendix for new algorithm 
Criterion and part of 
criterion to note Explanation 
Criterion 1 
“Reasonable time interval” 
- Refers to time present for drug to act in body 
- If the reaction comes on only after 5 half lives 
of the drug has passed since time of drug 




“Adverse reaction been 
associated with the 
suspected drug before” 
 
- Based on official reference (BNF, 
Micromedex, USPDI, etc) 
- If not sure whether such a reaction has been 




“Could this adverse 




- Existing clinical condition refers to condition 
which patient already has. Do not anticipate 
for possible clinical conditions which patients 
may have. 
- If not sure what clinical condition the patient 




“Any over-dose of the 
suspected drug” 
- ‘Over-dose’ here is inclusive of diminished 
elimination of the suspected drug as a result of 
drug interaction with another concomitant 
drug, or reduced renal or hepatic function. 
 
Criterion 5 
“If the drug was 
discontinued, did the 
adverse reaction improve 
within a reasonable period 
of time?” 
- When the drug is discontinued and a specific 
antagonist/antidote is given concurrently, 
please select the option ‘Do Not Know’ 
- If the drug brought about irreversible changes 
(e.g., organ failure), please select the option 
‘Do Not Know’ 
- “Within a reasonable period of time” indicates 
that the option ‘No’ should only be used after 





the suspected drug” 
- E.g., Digibind for digoxin, Vitamin K for 
warfarin, acetylcysteine for paracetamol 
- Not referring to treatment given to relieve 
symptoms of ADR 
 
Criteria 5 to 8 - Please use ‘Not Applicable’ when the 
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Table 6.9 Percentage differences in grading each criterion before and after the 
introduction of the appendix (n=50) 
Criteria in algorithm  
1 2 3 4 5 6 7 8 
Rater 1 8% 24% 22% 14% 16% 10% 0% 0% 
Rater 2 8% 28% 28% 14% 12% 8% 4% 0% 
Rater 3 10% 24% 24% 14% 6% 8% 4% 0% 
Average 8.7% 25.3% 24.7% 14.0% 11.3% 8.7% 2.7% 0.0% 
 
Table 6.10 Inter-rater agreement of the algorithm 
 Kappa values 
 Between rater 
1 & 2 
Between rater 
1 & 3 
Between rater 
2 & 3 
Before addition of appendix 0.617 0.660 0.483 
After addition of appendix 0.965 0.898 0.931 
 
 The Kappa values obtained from the inter-rater studies are presented in Table 
6.10. All the Kappa values of each inter-rater pair were significant at p<0.001. From 
the table, it shows that with the addition of an appendix to explain how to grade the 
various criteria for the algorithm, the range of Kappa values increased from 0.483 – 
0.660 to 0.898 – 0.965. 
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6.4 Discussion 
 In this study, genetic algorithm was used to generate the scores for the 
algorithm which was developed in the previous chapter, with the resultant final scores 
being quantitative instead of qualitative. Genetic algorithm is used in this study 
because the total number of scoring systems that have to be explored in order to find 
one which fulfils all the different reference points is too large to be practically done. 
Artificial intelligence methods like genetic algorithm are able to search through the 
vast pool of scoring systems in a reasonable time by rapidly eliminating those scoring 
systems which are obviously unsuitable and concentrating the search efforts on those 
scoring systems which have the potential to fulfil the different reference points. When 
this new algorithm is applied to specific ADR cases, the evaluator is now able to 
determine the probability of the involvement the suspected drug and the resultant 
ADR. This feature would be very informative in clinical decision making when the 
physicians can have more concise estimate of the likelihood of a drug causing an 
ADR. Besides its clinical applicability, this new algorithm is especially useful for 
regulatory agencies, as well as of great value in drug companies when conducting 
clinical trials.  
 
 The contribution of our new algorithm to clinical risk management would be 
particularly pronounced in allowing more rapid signal detection for new drugs and for 
rare ADRs. Undeniably, pharmacovigilance units in countries with large number of 
ADR reports can perform signal selection by using statistical parameters in impact 
analysis which quantitatively compare combinations of drugs and adverse events 
against the background of the database.115 A quantitative ADR algorithm like the one 
developed in this study, can be incorporated into the ‘Scoring for strengths and 
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weaknesses of the evidence’ segment to further increase the robustness of the existing 
analysis. 
 
 As for pharmacovigilance units in countries with smaller population and hence 
smaller number of consolidated reports, the knowledge of the likelihood of any 
received ADR reports caused by a suspected drug would allow the regulatory agency 
to use this information to warn prescribers as appropriate. Whereas in clinical trials, 
the ability to detect definite ADRs in Phase II and Phase III trials would provide 
invaluable information in deciding whether to continue with the trials as well as 
issuing extra caution for continuing trials. Extrapolating this to post-marketing 
surveillance studies (Phase IV trials), the acquiring of a quantitative ADR signal to 
pick up rare but definite ADRs will help to alert the drug companies on the need of 
withdrawing the offending drugs from the market, or to put in extra cautionary labels 
regarding the use of the drugs. 
 
 Other points about the new algorithm worth discussing are its sensitivity and 
specificity, and its performance against other algorithm used. From the results, the 
congruency between this new version of the algorithm and that of expert opinion is 
83.8%, about 60% higher than using the current CDA algorithm (adapted from 
guidelines used by ADRAC). Also comparing with the other established ADR 
algorithms (Table 6.7), the new version of the algorithm has the highest sensitivity of 
83.8% and lowest specificity of 71.0%. Therefore, using the new algorithm will result 
in more cases with definite ADRs being classified correctly. However, the seven 
algorithms are more superior in weeding out the non-definite ADR cases due to their 
higher accuracies in assigning ‘Not definite’ to ADR cases that are indeed not caused 
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by the suspected drug. Hence, our algorithm takes on a more conservative stand of 
suspecting that there is definite drug causality involved. From the public health 
perspective, this would be a desirable feature if an ADR algorithm is viewed as a 
screening test. This would be congruent with the concept of “Sn-N-out” of using 
screening test in the clinical setting. 
 
 Other than adopting a quantitative scoring method, an appendix was also 
added to the new algorithm with the purpose of reducing any possible ambiguity 
when applying the algorithm and to further reduce inter-rater disagreement. Even 
though the algorithm has already provided a specific sequence of steps to ensure 
reproducible results, without this appendix to clarify potential ambiguity resulting 
from the questions, judgmental intermediates may occur in the sequence thus altering 
the end results. The results showed that 2 criteria (Criteria 4 and 5) had more than 
10% change in their selected options (‘Yes’, ‘No’, ‘Do Not Know’, ‘Not Applicable’) 
between the absence and presence of the appendix, and another 2 criteria (Criteria 2 
and 3) had more than 20% change. A Kappa analysis carried out for inter-rater 
agreement showed that the agreement between raters were better (0.898 – 0.965) with 
the presence of the appendix, indicating an improvement in clarity after the appendix 
was added in. 
 
 In conclusion, the refining of the scoring system to reflect a quantitative scale 
and the addition of an appendix have helped to make the previously developed 
algorithm (see Chapter 5) more sensitive, and reduced the variability when used by 
different users. These strengths will give this algorithm an extra advantage when used 
by clinicians, regulatory agencies or drug companies to generate alerting ADR signals. 
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Using a quantitative method of assessing causality will also mean that rare ADRs and 
new ADRs that have not been documented can more readily be detected since a 
quantitative score can tell more precisely the likelihood of ADR causality. Therefore, 
by using a quantitative approach, a simple and easy to use ADR algorithm which 
would contribute to clinical risk management was developed. 
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7.1 Introduction 
 Adverse drug reactions (ADRs) are an unfortunate but often inevitable drug 
related problem in pharmacotherapy. Hence, ADR reporting is a major initiative in 
improving drug safety at both the institutional and national level in many healthcare 
systems with, pharmacovigilance forming part of drug regulation in many 
jurisdiction.35 As mentioned in previous chapters, spontaneous reporting of suspected 
adverse reactions to drugs is currently the backbone of such pharmacovigilance.35 
However, this is not the ideal method as spontaneous reporting often produces only 
circumstantial evidence, with uncertainties pertaining to the causal involvement of the 
drugs.36 Further assessments, which include measuring frequency, identifying risk 
factors and explaining the mechanisms of the ADRs, are therefore needed in order to 
allow a more definite confirmation of causality. 
 
 As discussed previously, clinically speaking, the most important criterion for 
assessing ADRs is its causality, which is the likelihood of the suspected drug causing 
the ADR. Such differential assessment of ADRs can be achieved with the use of 
clinical judgments alone or in combination with algorithms.66 Algorithms are a set of 
questionnaires that determine drug causation in the occurrence of an ADR by 
checking the temporal association between drug administration and the onset of the 
adverse drug event. The use of algorithms help to improve the reliability of 
assessments, decrease inter- and intra-rater disagreement,58 and give a better guide in 
making complex clinical decisions than clinical judgment alone.100 However, one of 
the major drawbacks is that most commonly used algorithms use a qualitative 
approach in assessing ADR causality. In the previous chapter, we reported the 
development of a simple ADR assessment algorithm with a quantitative scoring 
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system based on the genetic algorithm, an artificial intelligence approach. The results 
from applying the algorithm showed that this algorithm could provide the decision 
maker with the likelihood of a reported ADR being caused by the suspected drug, thus 
allowing a more informed and accurate differentiation between signals and noises. 
Additionally, the new algorithm has demonstrated good sensitivity as a screening test 
for suspected ADRs. 
 
 Regardless of whether an ADR algorithm is using the conventional qualitative 
approach or the quantitative approach as provided by our algorithm reported in 
previous chapters, it can only provide information of the possible causality (or even 
likelihood) of a drug in the occurrence of an ADR. However, information on how 
severe the ADR may be is lacking from the assessment when using such algorithms. 
In order to give the most appropriate response to any reported ADR, it is imperative 
that both the likelihood of causality as well as the severity of the ADR be known and 
correlated. For example, it would still be appropriate to initiate the “alert” response 
when an ADR with higher level of “severity” but low to moderate probability of 
causality is encountered. 
 
 This raises the issue of the definition of severity for ADR reporting. Based on 
the definitions provided by World Health Organisation – Uppsala Monitoring Centre 
(WHO-UMC), the term ‘severe’ is used to describe the intensity of a specific event. 
That is, if the event is mild, moderate or severe.116 This is unlike seriousness, which is 
based on either outcome or action criteria, and serves as a guide for defining 
regulatory reporting obligations.116 From literature search, several published studies 
related to ADR detection, reporting and prevention also mentioned that ADR severity 
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were being investigated.117-120 Unfortunately, different researchers have their own 
method of defining the various levels of severity. Some researchers do mention how 
they define the various levels (Figure 7.1), whereas some don’t. The literatures cited 
in Figure 7.1 are definitely not exhaustive; there are many other publications which 
used their own definition when assessing the severity levels of adverse reactions or 
side effects from pharmacotherapy.121 In 2001, Loke et al. did a literature review to 
study details on the severity of the reported ADRs.121 For ADRs with severity 
reported, they investigated how these severity scales were defined. From their search, 
it was found that the severity levels used in many studies were not defined. The 
severity scales used were broadly classified as ‘Mild’, ‘Moderate’ and ‘Severe’ ADRs. 
So far, we only came across one study which used a scoring system to determine the 
severity level of the ADRs.122 In that study, Dormann et al. used a questionnaire with 
11 criteria and each criterion was assigned a different weightage to assess ADR 
severity. Based on the total score derived from the questionnaire, different intensities 
of severity were then assigned. 
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Figure 7.1 Some severity assessments which define the severity levels used 
 
Examples of studies that 
gave explanation of the 
ADR severity levels used Bentancourt BY et al. 
Definition of levels 
Mild: No therapy was necessary 
Moderate: Need specific 
treatment 
Severe: Require hospitalization 
or prolongation of 
hospitalization 
Very Severe: Potentially life-
threatening or contributed to 
patient’s death 
Prosser TR et al. 
Definition of levels 
 
M0: Not related to drug therapy 
M1: Drug discontinued, no additional 
treatment needed to reverse reaction 
M2: Drug benefits exceed risks 
M3: Additional treatment needed to 
reverse reaction 
M4: Irreversible injury or aggressive 
treatment required 
M5: Death directly related to ADR 
Hartwig SC et al. 
Definition of levels 
 
1: An ADR occurs but requires no change in 
treatment with the suspected drug 
2: The ADR requires that the suspected drug be 
withheld, discontinued, or otherwise changed. No 
antidote or other treatment is required, and there is 
no increase in length of stay. 
3: The ADR requires that the suspected drug be 
withheld, discontinued, or otherwise changed, 
and/or an antidote or other treatment is required. 
There is no increase in length of stay. 
4(a): Any level 3 ADR that increases length of 
stay by at least one day 
4(b): The ADR is the reason for admission 
5: Any level 4 ADR that requires intensive medical 
care 
6: The ADR causes permanent harm 
7: The ADR either directly or indirectly leads to 
the death of the patient. 
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 From these published severity assessments, the obvious and logical trend is 
that all of the studies attempted to classify the ADR severities into scales of increasing 
intensity. However, the various assessments had different number of intensity levels - 
Dormann et al. had 3,122 Bentancourt BY et al. had 4,118 Prosser TR et al. had 6,119 
and Hartwig SC et al. had 8 levels.123 Nevertheless, these severity assessments of 
ADRs will not be useful if they were used independently. As previously mentioned, 
an ADR of high severity is not meaningful if the cause of the ADR is not known. 
Hence, there is a need for both drug causality and ADR severity to be determined 
concurrently. With the knowledge of both causality and severity of the suspected 
ADR, it would serve to aid regulatory authorities in making decisions on whether the 
drug causing the ADR should be re-evaluated for the suitability of its indicated use, or 
should there be special cautionary labels which the manufacturers need to put in for 
the particular drug. For the clinicians, this information can assist in judging the risk-
benefit ratio of using the drugs involved in ADRs to treat a condition, or whether an 
alternative drug should be used. In the case of drug trials, this knowledge would 
facilitate the investigators or the sponsor companies in deciding if there is a need to 
break the code for a blinded-study, to increase trial monitoring or even to halt the 
conduction of the trial. 
 
 In this chapter, an attempt to develop a severity assessment scale that is 
straightforward to use and accurate in presenting the severity of ADRs is reported. 
This severity assessment scale would be incorporated into the previously reported 
ADR causality assessment scale (see Chapter 6). The fundamental approach is to 
combine both ADR causality and severity analysis to give an overall assessment 
which is presented as various “alert” zones. This approach is to increase the utilitarian 
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factor of this combined causality and severity assessment in helping the user 
determine the appropriate course of action to be taken, following the particular ADR 
detection. 
 
 Once the combined assessment is developed, an online version of the 
assessment to help users with the calculation of scores and assignment of alert zones 
will be made available. 
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7.2 Methods 
7.2.1 Approach in Designing the Severity Scoring System 
 In order to construct a severity assessment scale, the first step was to develop a 
number of categories with increasing intensities of severity. After that, a particular 
score was given to the different levels of severity, with the lowest for the level with 
the least severity and ascend at regular interval to reach a highest score for a lethal 
ADR. This assigned score was an arbitrary number and its absolute value is not 
important. The importance lied with the relative scale between the different levels of 
severity. That is, a higher score would represent a more intense severity for the 
adverse reaction experienced. 
 
 To give more meaning and function to the severity scores, they were 
combined with the scores derived from an ADR causality probability algorithm which 
was reported in previous chapter (see Chapter 6) to form a combined scoring and 
assessment system. This combined scoring system from both the causality and 
severity assessment scales would be translated into three different colour zones – 
green, amber, and red.  
 
 Green zone would signify that the ADR is mild or most probably not even due 
to the suspected drug. There is not need to place too much emphasis or resources into 
an ADR that is classified under the green zone. Amber refers to an ADR that has a 
higher level of severity and coupled with the fact that it is of higher probable drug 
causality, medical personnel or regulatory authorities need to continue to monitor the 
use of the offending drug. For the red alert zone, the ADR is of a severity that is high 
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enough for the authorities to stop using the offending drug, or to completely withdraw 
the use of the drug. 
 
7.2.2 Rules for Assigning Severity Scores 
 In order to produce the combined system, some rules for different scenarios 
had to be determined. These rules should be universally accepted as logical to assign 
different ADR cases with varying causality and severity scores into one of the three 
colour zones.  
 
 For Rule 1, when an ADR is determined as ‘Definite’ based on the previous 
probability scoring system that was reported in the earlier chapter (See Table 7.2, Part 
1), and if the patient requires intensive care, experience irreversible harm or death, 
such an ADR case will immediately be admitted into the red alert zone.  
 
 Rule 2 will denote that if ADR is of ‘Definite’ causality but the patient only 
need out-patient attention or require in-patient care (but excluding intensive care), 
these cases will be classified under the amber alert zone. These “amber alert” cases 
would require further observation to determine how should the offending drug be 
dealt with. This allowance was made for ‘Definite’ causalities with requirement for 
both in-patient and out-patient care to address the fact that patients with the same 
ADR may present with symptoms of different severity, and physicians may react to 
them in different manner where the decision of keeping them warded is concerned.  
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 For Rule 3, ‘Definite’ ADR causalities that do not require any form of 
intervention will be deemed to fit into the green alert zone. With the above 3 rules, all 
‘Definite’ ADR cases can be classified into the three zones. 
 
 For ‘Probable’ and ‘Possible’ causality cases, they will be considered as under 
the red alert zones if they give rise to irreversible harm or fatality (Rule 4).  
 
 If the ‘Probable’ and ‘Possible’ cases require intensive care, then they will be 
admitted into the amber alert zone (Rule 5). Though these ADRs are severe enough to 
require intensive care, the fact that there is doubt if the ADR is caused by the 
suspected drug once again puts them into the “observe and manage” category. 
 
 ‘Unlikely’ ADR causality cases that result in irreversible harm to the patients 
will be classified under the amber alert zone for further observation to evaluate if 
there is a more intimate causality relationship between the drug and the ADR (Rule 6).  
 
 However, if the ADR is ‘Unlikely’ and if patient does not suffer from 
irreversible harm or fatality, then this will be classified into the green alert zone (Rule 
7). . It is difficult to determine logically the appropriate zone alert for ‘Probable’ or 
‘Possible’ ADRs with patients requiring only out-patient or in-patient treatment. So, 
the final zone alert for these cases will be determined based on an analysis of all the 
different rules and not on direct logic. Thus, with Rules 6 and 7, all ‘Unlikely’ ADR 
cases can be classified into one of the three alert zones. 
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7.2.3 Constructing the Border between the Different Alert Zones 
 A chart which summarized the above rules for the various scenarios would 
then be developed. 200 x 6 = 1200 data points were generated by varying the 
causality scores from 0 to 1, at intervals of 0.005 and by varying through the six 
severity level. The data points were then classified into one of the three zones using 
the seven rules shown above. Data points that are not classifiable based on the seven 
rules are removed. The remaining points are plotted on a chart with severity scores on 
the y axis and causality scores on the x axis. Each point is coloured based on its zone 
alert classification.  
 
 Since some of the original 1200 data points are unclassifiable and thus 
removed, there will be gaps in the chart. These gaps are filled by extrapolating from 
those data points which can be classified. This chart will provide a visual aid to users 
in determining the appropriate alert zone when the severity score and causality score 
is known. This is to help the user in determining the alert zones after they have 
determined the drug causality and severity of the ADRs. It will also help to classify 
those cases which cannot be classified through logic. 
 
 A final score is then calculated from the severity score and causality score by 
taking the average of the two scores. Using this final score, different priorities can be 
assigned to different cases that are in the same alert zone. For example if two cases 
are in the amber zone and case A has a final score of 0.471 and case B has a score of 
0.571, then case B should receive more attention than case A since it is nearer to the 
red zone than case A. 
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7.2.4 
7.2.5 
Development of online version of new algorithm 
 At the same time, an online version of this combined scoring and assessment 
system was developed. The objective of this is to provide the user with an easily 
accessible and simple to use tool for determining the alert zone of ADR cases. The 
online version also provides a checking mechanism to detect any inconsistencies in 
the ADR report. 
 
Testing of the New Algorithm 
 With the newly merged causality and severity scoring system, 10 ADR cases 
with varying drug causality were used to illustrate how this assessment system can be 
used. The ADR cases were taken from ADR reports received by the 
Pharmacovigilance Unit in the Centre for Drug Administration (CDA), Health 
Sciences Authority, Singapore, during the period of January 2002 and March 2003. 
As previously reported, this unit is the national body in Singapore handling ADR 
monitoring. 
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7.3 Results 
 With reference to existing severity scales used by various researchers,56, 122, 123 
an assessment scale with 6 different severity levels, denoted as S1 to S6 (Table 7.1) 
was developed. These levels are meant to show increasing intensities of the ADRs 
since the levels from S1 to S6 demonstrates ascending requirement for more dire 
measures to manage the ADR. The arbitrary scores assigned to the different levels can 
be seen in Part 2 of Table 7.2. The scores start from 0 for the severity with the mildest 
intensity and increase in steps of 0.2 for each increasing level of severity. When the 
ADR is fatal, the severity score will be the highest at 1. 
 




S1 Offending drug may or may not be withheld, no treatment required 
S2 Offending drug to be withheld, out-patient treatment is required 
S3 Offending drug to be withheld, in-patient treatment is required 
S4 Intensive care is required but patient does not suffer any disability 
S5 Patient suffer irreversible harm (including physical disability) 
S6 Patient died as a result of the reaction (either directly or indirectly) 
 
 This severity assessment scale will be used together with the quantitative 
algorithm for ADR causality which was developed earlier (see Chapter 6). The 
combined scoring system can be seen in Table 7.2. Part 1 of Table 7.2 enables the 
algorithm to identify the probability that a particular ADR is indeed caused by the 
suspected drug. Part 2 of this table on the other hand provides the newly developed 
severity scale with the corresponding severity score which was mentioned earlier.  
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 To obtain the combined score for both causality and severity, the average of 
the two scores attained by running Part 1 and Part 2 through a given ADR case or 
report was used. The formula for calculation of the final score is provided in Part 3 of 
Table 7.2. The chart in Part 4 is to help determine the alert zone for the ADR. The 
vertical axis of the chart denotes the different severity levels, whereas the horizontal 
axis represents the causality probability. With both the causality probability value, 
calculated from Part 1 of Table 7.2, and the corresponding severity level, the user will 
be able to locate the intersection point on the chart and determine the alert zone which 
the ADR will be assigned.  
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Table 7.2 Combined ADR causality and severity scoring system 
 Part 1: ADR Section (Appendix A should be used concurrently) 





1 Is there a reasonable time interval between 
administration of the suspected drug and 
the adverse reaction? 
49 0 36 - 
2 Has the adverse reaction been associated 
with the suspected drug before? 
1 0 0 - 
3 Could this adverse reaction be due to an 
existing clinical condition? 
0 7 1 - 
4 Is there any over-dose of the suspected 
drug? 
2 0 0 - 
5 If the drug was discontinued, did the 
adverse reaction improve within a 
reasonable period of time? 
14 0 7 7 
6 If the drug was NOT discontinued, did the 
reaction resolved on its own? 
0 1 0 0 
7 Did the reaction improve when specific 
antagonist/antidote towards the suspected 
drug was administered? 
17 0 1 1 
8 Did the adverse reaction recur when the 
suspected drug was discontinued and re-
administered? 
33 0 17 17 
 Circle the relevant option for each question and add up the score for Part 1 
 Total score, T: 
 
    
 Probability, P = (T - 8) / 108:  
 
    
Causality categories: Definite: 0.75 ≤ P ≤ 1; Probable: 0.63 ≤ P < 0.75; Possible: 
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PART 3: FORMULA FOR FINAL 
SCORE, F 
 
Average score of Part 1 and Part 2: 
(P + S) / 2 = F  
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Appendix A 
Criterion and part of 
criterion to note Explanation 
Criterion 1 
“Reasonable time interval” 
- Refers to time present for drug to act in body 
- If the reaction comes on only after 5 half lives 
of the drug has passed since time of drug 




“Adverse reaction been 
associated with the 
suspected drug before” 
 
- Based on official reference (BNF, 
Micromedex, USPDI, etc) 
- If not sure whether such a reaction has been 




“Could this adverse 




- Existing clinical condition refers to condition 
which patient already has. Do not anticipate 
for possible clinical conditions which patients 
may have. 
- If not sure what clinical condition the patient 




“Any over-dose of the 
suspected drug” 
- ‘Over-dose’ here is inclusive of diminished 
elimination of the suspected drug as a result of 
drug interaction with another concomitant 
drug, or reduced renal or hepatic function. 
 
Criterion 5 
“If the drug was 
discontinued, did the 
adverse reaction improve 
within a reasonable period 
of time?” 
- When the drug is discontinued and a specific 
antagonist/antidote is given concurrently, 
please select the option ‘Do Not Know’ 
- If the drug brought about irreversible changes 
(e.g., organ failure), please select the option 
‘Do Not Know’ 
- “Within a reasonable period of time” indicates 
that the option ‘No’ should only be used after 





the suspected drug” 
- E.g., Digibind for digoxin, Vitamin K for 
warfarin, acetylcysteine for paracetamol 
- Not referring to treatment given to relieve 
symptoms of ADR 
 
Criteria 5 to 8 - Please use ‘Not Applicable’ when the 
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 The online version of the combined scoring system can be found at 
http://staff.science.nus.edu.sg/~phalisc/abacus/ (Figure 7.2). The usage of the online 
scoring system is very simple. The user will input the options (‘Yes’, ‘No’, ‘Do not 
know’, ‘Not applicable’) to the various criteria for individual ADR reports by clicking 
the relevant radio buttons. At the same time, the user will have to input the severity 
level of the ADR. On clicking the ‘Calculate’ button, the probability of the ADR 
causality of the suspected drug will be calculated. Simultaneously, the alert zone of 
the ADR will be determined and presented in a box which the ADR causality will be 
presented. The background of this box will reflect a corresponding ‘Green’, ‘Amber’ 
or ‘Red’ colour. The online assessment system also has a batch job option. The user 
can input the options to the various criteria for several ADR reports on a Microsoft 
Excel spreadsheet, and then copy and paste these data onto the text box provided on 
the webpage. The alert zone for each of these ADR reports will then be given to the 
user on another text box. 
 
 
Chapter 7: Alerts Based on ADRs’ Causality and Severity (ABACUS) 162
Figure 7.2 Online version of combined scoring system 
 
  
 The case description of the 10 chosen ADR cases used for illustrating the 
application of the combined causality and severity scoring system are presented in 
Tables 7.3 and 7.4. The figures ‘Probability of Causality’ column were determined 
from Part 1 of Table 7.2.  
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Table 7.3 Actual cases to illustrate use of combined causality and severity 
scoring system (first part) 










1 A patient developed muscle ache 
whilst taking pravastatin 20mg every 
night. The muscle ache went away 










2 A 45 year old patient presented with 
light-headedness and raised creatine 
kinase and aldolase after a single 
dose of sildenafil citrate. The patient 










3 A male patient was on a 
complementary medicine which 
contained ephedrine for many 
months before he presented with 
vomiting, increased drowsiness and 
jaundice. A diagnosis for acute liver 










4 Patient with no known drug allergy 
developed pruritus after taking 










5 Patient developed oedema of the 
face after ingesting a single dose of 
40mg omeprazole for 
gastroesophageal reflux disease. 
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Table 7.4 Actual cases to illustrate use of combined causality and severity 
scoring system (second part) 










6 Patient developed generalized 
erythematous, pruritic rash, as well 
as shortness of breath and 
involuntary irregular jerking of 
upper and lower limbs after 
receiving 100mg of intravenous 
paclitaxel for ovarian carcinoma. 










7 Patient developed bronchospasm 
and collapsed airways upon 
receiving intravenous Iohexol for 
urography. He was intubated and 
ventilated in the intensive care unit 










8 Patient developed a mild, transient 
rash around the face and arms, with 
some slight pruritus upon receiving 
120ml of intravenous Ioparmro for 
CT scan of the abdomen. Patient 









9 A 51 year old male patient presented 
with an intense urge to fall asleep 
without warning within 1 – 2 hours 
after consuming 100mg of piribedil. 
This symptom resolved when 










10 Patient presented with low platelet 
count after taking rofecoxib 25mg 
daily for 6 months to manage her 
osteoarthritic knee. Her platelet 
count returned to normal following a 
de-challenge but decreased again 
when rofecoxib therapy was re-
introduced. Therapy with rofecoxib 
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7.4 Discussion 
 The main purpose for this study is to develop a severity assessment scale to 
compare the intensities of severity of various adverse drug reactions. This scale was 
then incorporated with a previously developed quantitative ADR causality scale (see 
Chapter 6) to give a combined ADR causality and severity scoring system. The idea 
of such a combined scoring system is to give more practical value to the results 
obtained compared to the individual causality and severity scores. 
 
 For the severity assessment scale, 6 different severity levels which are 
distinctly different from each other were used. This is done with the intention of 
providing the user with well-defined severity categories so that there will be no 
ambiguity in interpreting the severity of the reactions.  
 
 Each level was represented with a code (S1, S2, S3, S4, S5 and S6) and a 
corresponding score. This is to minimize confusion with terms like ‘Mild’, 
‘Moderate’, ‘Severe’ since they are subjective and very much relative to a particular 
starting point. These severity levels and scores may not be of much significance on 
their own, but when coupled with the probability score from the ADR causality 
algorithm, a specific level of alert can be tagged onto the drug suspected to cause the 
ADR. The quantitative scoring system adopted can also aid in triage where there is a 
need to prioritize cases for management. This is evident in the cases which are 
presented in Tables 7.3 and 7.4. 
 
 From Tables 7.3 and 7.4, based on the cases and the resultant alert zones, it 
can be observed that although drug causality were the same, dissimilarities in severity 
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levels resulted in the cases being assigned to different alert zones. Hence, even though 
the cases have the same causality, they will still warrant different levels of attention. 
This can be seen in case 2 and case 3. They share exactly the same probability score 
for ADR causality but because case 3 has a higher level of severity since it required 
intensive care treatment compared to case 2 which only required in-patient attention, 
case 3 is classified into the red zone compared to case 2 which goes into the amber 
zone. 
 
 The combined scoring system which was developed can also be used 
quantitatively. This can be exemplified in case 5 and case 6. Even though both are in 
the amber zone, a higher score for case 6 compared to case 5 indicates that the drug 
involved in case 6 should receive a higher priority for further investigation or other 
actions since it is a step closer to the red alert zone compared to case 5. 
 
 Another important point that can be demonstrated using the cases assessed is 
that a ‘Definite’ ADR may not be as severe as a ‘Possible’ or ‘Probable’ ADR (See 
case 3, 7 and 8 in Tables 7.3 and 7.4). Hence, in a situation when there is a need to 
prioritize management of cases, those in the red alert zones should be dealt with first 
despite it having a lower causality score than another ADR in the green or amber 
zones. 
 
 Hence, with this combined ADR causality and severity scoring system, 
important information like whether a drug is likely to cause an adverse reaction and 
whether it is dangerous enough to be withheld or necessitate further investigation on 
its potential dangers can be obtained. This will be useful from medical practice and 
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clinical trials points of view, as well as from drug-regulation aspect. For the clinicians, 
this scoring system serves as a fast and convenient way of identifying true and 
hazardous ADRs. In the case of clinical trials, when the adverse effects of a drug are 
not yet well established, using such a scoring system can bring about more efficient 
management of the possible ADRs and prompt decisions can be made with regard to 
discontinue the trials or in less drastic measures, to just provide additional 
precautionary labels for the drug involved. Where drug regulatory authorities are 
concerned, having such convenient method of ADR identification and classification 
can be a preliminary step leading to further inquiry or dissemination of nation-wide 
alerts. This will be especially useful in small pharmacovigilance centres that do not 
have access to vast amount of ADR data and hence more difficult to produce signal 
alerts from ADR reporting data.  
 
 The online version of the combined scoring and assessment system has some 
features incorporated into it to aid in its user-friendliness. A ‘Help’ icon is provided at 
the end of each criterion. The ‘Help’ icons provide information that is present in the 
appendix section of the ADR causality portion. The user will just have to roll the 
cursor over the icon to get a dialog box giving relevant instructions to reduce possible 
ambiguities to the question to be answered. Another added feature in this online 
version is its ability to detect any inconsistencies in the ADR report. For example, if 
the option for Question 5: “If the drug was discontinued, did the adverse reaction 
improve within a reasonable period of time?” is chosen as ‘Yes’, and that for 
Question 6: “If the drug was NOT discontinued, did the reaction resolved on its 
own?” is chosen as ‘Yes’ as well, the algorithm is programmed to highlight both 
options and inform the user that there are inconsistencies in the ADR report. The user 
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can roll the cursor over the highlighted options to get a dialog box giving the reasons 
for the suspected inconsistencies and instructions for correcting the inconsistencies. 
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7.5 Conclusion 
 In conclusion, a combined ADR causality and severity assessment system has 
been developed, including an online edition. Such a system can be utilized to help a 
clinician, principle investigator or even regulatory authority to determine the course of 
action to be taken, following a particular ADR detection. With its quantitative nature, 
the scoring system can also aid clinicians in their case management when there is 
limited time and resources. With further fine tuning and more extensive testing, it 
would provide a handy tool for healthcare deliverers, drug regulators and clinical trial 
coordinators in risk management.  
 










Chapter 8  
Overall Conclusion 
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8.1 Major findings 
In this finale chapter, a summary of the major findings which were presented in the 
past chapters will be given. 
 
First, a recap of the research questions to show the original intent of the project:  
1. What is the current DRP situation in Singapore like? Is it different from 
the situation as reported in overseas studies?  
2. Will the patients being managed under the current system in the hospital 
benefit from the presence of physician-pharmacist review teams? Will 
DRPs and medication costs be reduced as a result of the presence of such a 
team? What would be the impact of such a team on the clinical and 
economic outcomes among in-patients (who supposedly would be more 
susceptible to DRPs due to the more severe nature of their medical 
conditions and hence would also consume more valuable healthcare 
resources)? 
3. Can the inadequacies present in some currently available ADR algorithms 
be addressed and improved upon? How can an ADR algorithm be further 
harnessed and develop it into a functional tool for detecting and assessing 
ADRs? 
 
  In essence, the main objective of the project was to evaluate whether 
pharmacists can contribute significantly with a review of managing risk among 
patients within the current healthcare system in Singapore. 
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 In order to answer the aforementioned questions, the authors have performed a 
study that attempted to establish the current situation as to the level of risk that the 
patients were exposed to in the healthcare environment, as well as to ascertain the 
contributory factors for the increased risk. This was followed by an attempt to 
evaluate the impact, both clinically and economically, on increased and systematic 
involvement by pharmacists in reducing these risks. After evaluating the impact of the 
system, the authors also proceeded to develop a quantitative tool in assessing ADR 
with the view that risk of DRPs, namely ADR could be greatly reduced with a better 
tool in an improved healthcare environment. 
 
These studies yielded the following findings: 
1. Chapter 2 of this thesis was intended to be a baseline study of the current 
situation in Singapore. The results obtained from this initial baseline study 
of risk assessment suggest that the incidence of drug therapy related 
admission to hospital in Singapore is comparable to that occurring in other 
developed countries. Of the major causes of drug-related hospital 
admissions, non-compliance was the most common cause of DRP, 
followed by ADRs.  
 
More importantly, all the identified ADRs were found to be avoidable if 
the patients were monitored closely. This finding that the DRPs were 
mainly avoidable provided a basis to derive suitable strategies to lower the 
incidence of drug therapy related hospital admissions. Although the results 
obtained did not demonstrate any statistically significant difference in 
DRP-associated hospital admission between geriatrics and younger 
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patients, probably due to the small sample size of the study, there is indeed 
an observed increased trend among geriatric patients which would be of 
clinical importance.  
 
2. Once again, the next study which was reported and detailed in Chapter 3 
investigated the DRPs in local hospitalized patients, so by and large, this 
was another risk assessment study in the local context. The results from 
this study established that the situation of drug therapy related problems in 
the group of patients receiving polypharmacy is again comparable to that 
occurring in other developed countries. One important interpretation of 
this would be that although the problem of DRP has been studied and 
reported for the past twenty years, lessons and experiences from these 
studies and different countries have not exactly been translated into 
effective management of these problems. With regards to risk factors 
identified, results from the study showed that among patients with 
polypharmacy, age and gender may not be as important as the number of 
drugs prescribed as predictors of experiencing a DRP. In the case of the 
study, neither older nor female patients have been reported as predictor of 
increased risk of developing DRP. However, this observation may be 
confounded by the inclusion criteria imposed by the study design. 
Nevertheless, the results from the study did show that the drugs causing 
DRPs locally are similar to those in overseas studies.77, 90 With this finding, 
healthcare professionals could at least pay more attention in monitoring 
patients prescribed these drugs.  
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Based on these abovementioned findings, the researchers would advocate 
applying the 20/80 principle in business management into clinical risk 
management. By identifying and properly managing the small percentage 
of patients with high risks for developing DRPs and those prescribed drugs 
commonly associated with DRPs, strategies can be created to minimize or 
prevent most of these DRPs. It is believed that with such an approach in 
resource optimization, the rampaging problem of DRPs can be at least 
dampened. 
 
3. The next study carried out in this thesis as reported in Chapter 4 was to 
evaluate whether the involvement of a pharmacist as a regular member in 
clinical ward round would be a cost-effective strategy in risk management 
under the current healthcare system. Upon investigating the impact of the 
pharmacist’s participation in a physician-pharmacist review team, the 
study showed that although the average length of stay in the group with a 
pharmacist in the patient care team was not significantly shorter than the 
group without a pharmacist, other benefits were reaped from the presence 
of a pharmacist. With the presence of a pharmacist, more drug related 
problems were detected and these problems were therefore promptly 
averted. The total drug cost savings during the 4-month study period when 
there was a pharmacist on board such a primary patient care team was 
S$14,036.40 and the calculated cost-benefit ratio of such an arrangement 
was 5.84. On top of this positive ratio, a net annual return of S$42,109.20 
in investing in a pharmacist to perform such monitoring tasks seems to 
substantiate the cost-effectiveness for the hospital administrators to 
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endorse the inclusion of a pharmacist to provide such pharmaceutical care 
services. The total hospital charge savings during the 4-month period on 
the other hand was also substantially high at S$66,373.20, and the cost-
benefit ratio from this is 27.66. The benefits to the patients would even be 
much greater if the impact on quality in life caused by the potential DRPs 
were taken into consideration.  
 
However, the finding from the study also demonstrated that under the 
current healthcare structure at the public institutes, the pharmacists are too 
over-burdened with the role and function of dispensing and distribution of 
medicine, and would not be able to have the time to perform other 
functions in a persistent and regular manner.  
 
4. In Chapter 5 of the thesis, after evaluating the impact on risk management 
by involving a pharmacist as a regular member of clinical ward round, the 
authors proceeded to evaluate whether the currently available tools in 
assessing ADR need improvement so that the pharmacist in the team 
would be better equipped to deal with the demands of their new role. The 
rationale for the study was based on the finding from the baseline study (as 
presented in Chapter 2) that ADR was one of the most common cause of 
hospital admissions and most of the ADRs were avoidable. Therefore, a 
simple and reliable ADR assessment algorithm would be a handy tool for 
the pharmacist as a regular member of the clinical ward round team. 
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By evaluating the advantages and disadvantages of several established 
algorithms for assigning ADR causality, a simple algorithm that provides 
ease of use and requires no extra data collection than those routinely 
collected in most ADR reporting forms was developed. In terms of 
performance, the new and shorter algorithm can achieve similar result as 
compared with a much more comprehensive algorithm. In addition, the 
new algorithm adopts a lower threshold in assigning “definite” ADR cases 
than most established algorithms, a feature that may be desirable in the 
context of public safety. On the whole, this algorithm would provide 
pharmacists, clinicians and drug regulators with a handy tool to assign 
ADR causality. 
 
5. In Chapter 6, a study was carried out to further fine-tune the newly 
developed algorithm so that the pharmacists or other healthcare 
professionals can be more certain about the likelihood of the ADR being 
caused by the suspected drug. This was achieved by, further refining the 
scoring system of the newly developed algorithm using genetic algorithm 
to reflect a quantitative scale. The further addition of an appendix also 
helped to make the algorithm more sensitive, and reduced the variability 
when used by different users. These strengths will give this algorithm an 
extra advantage when used by clinicians, regulatory agencies or drug 
companies to generate alerting ADR signals. Using a quantitative method 
of assessing causality will also mean that rare ADRs and new ADRs that 
have not been documented can be more readily detected since a 
quantitative score can indicate more precisely the likelihood of ADR 
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causality. Therefore, by using a quantitative approach, a simple and easy to 
use ADR algorithm which would contribute to clinical risk management 
was produced. 
 
6. In Chapter 7 of the thesis, a further study was performed to incorporate 
another important feature in assessing ADR to make the newly developed 
algorithm a more useful tool in risk management.  
 
A severity assessment scale for ADRs was developed to objectively 
compare the intensities of the severity of various ADRs. This scale was 
then incorporated with the quantitative ADR causality scale which is 
mentioned above. This amalgamation provides a novel combined ADR 
causality and severity scoring system which will serve to give more 
practical value to the results obtained compared to the individual causality 
and severity scores. Herewith, information like whether a drug is likely to 
cause an adverse reaction and if it is dangerous enough to be withheld 
from normal usage or if there is a necessity to perform further risk 
assessment on its potential can be acquired.  
 
An online version of this combined scoring and assessment system has 
also been developed. Features which will increase its user-friendliness 
have also been incorporated into this online edition. 
 
 
Chapter 8: Overall Conclusion 178
8.2 Contributions 
 The motivation of the current thesis resulted from wanting to identify and 
assess the most exact state of DRPs and ADRs in Singapore. With the knowledge of a 
more exact representation of the situation locally, it will then be possible to develop 
and implement strategies which will help in detecting, assessing and managing the 
situation of DRPs locally. 
 
 This thesis has indeed achieved the above purpose. A formal study on the 
prevalence of DRPs in Singapore was done and baseline results with regards to the 
exact state of DRPs and ADRs were obtained. With these results, a further study to 
assess whether having a pharmacist on a primary patient care review team on a 
regular basis will help to improve the situation of in-patients developing DRPs was 
performed. At the same time, the authors were interested in finding out if having a 
pharmacist permanently on such review teams will be a cost-effective measure. Both 
objectives were accomplished and the results suggest that it is indeed cost-effective to 
have pharmacists on board such teams. The cost-benefit ratio of such pharmacists’ 
services, in addition to a possible improvement in in-patients’ health related quality of 
life with the presence of pharmaceutical care (because of the detection and 
elimination of existing or potential DRPs) can help the pharmacy department in the 
hospital put forth proposals for the hospital administrators to increase their budget for 
the implementation of such clinical pharmacy services. 
 
 Emerging from the baseline study of the exact state of DRPs and ADRs in a 
local acute hospital also highlighted the large number of ADRs in Singapore. Since 
ADRs have the propensity to bring about dire consequences where mortality, health-
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care resources and health-care costs are concerned, a method to detect these ADRs 
and consequently bring about management of such drug risks is required. The novel 
combined ADR causality and severity assessment system which was developed in the 
course of this study is intended for indicating ADR alerts. However, other than the 
initial target audience – the clinicians, this combined scoring system, ABACUS 
(Alerts Based on ADRs’ Causality and Severity), can also help investigators in 
clinical trials and regulatory authorities to determine the course of action to be taken 
following a particular ADR detection. ABACUS can be utilized to facilitate signal 
generation of drugs on the whole or for targeted drugs that the clinicians or authorities 
have interest in. The quantitative nature of ABACUS can also help clinicians, 
investigators and the authorities in case management when they are faced with limited 
time and resources. This scoring system will also be a useful tool for pharmacists in 
patient care review team for the purpose of detecting ADRs in the in-patients. An 
online version of ABACUS, equipped with its user-friendly interface and automatic 
calculation of scores was furthermore developed. This was done to allow convenience 
and ease of use of this scoring system. 
 
 In view of the results obtained from these studies, it could be inferred that with 
a change in the workflow of the current healthcare system in Singapore and by 
equipping the pharmacists with user-friendlier and simple tools (e.g. the algorithm 
developed in this thesis), it would be possible to allow the pharmacists to play a much 
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8.3 Limitations 
 The researchers acknowledge that the baseline study for the prevalence of 
DRPs was a retrospective one and the study was only performed in patients on 
polypharmacy. The retrospective nature was because by the time the study was 
embarked on, the acute hospital which was collaborating in the study already had 
pharmacists going around the wards monitoring patients’ medication therapy. Hence, 
a prospective study will not be able to give a clean baseline where there is no 
intervention performed as it is unethical to prevent the pharmacists from carrying out 
their intervention work, though not on a regular basis. Due to the retrospective nature, 
requests for case-notes of patients from the medical record office to extract the 
relevant data had to be done. This meant that any information which was not provided 
or not clearly provided in the case-notes could not be used nor be reflected in the 
study. The retrospective nature of the study also brought about a limit to the number 
of cases that could be requested from the medical record office during the study 
period. Hence, only patients on polypharmacy were included in the study. However, 
prior to deciding on whether to include only patients on polypharmacy, a literature 
search was performed and it was confirmed that in the past two decades, most of the 
drug related problems encountered came from patients who were on polypharmacy. 
Hence, the results that were obtained should not be too skewed as a result of this 
limitation. 
 
 The study that was carried out on pharmacists’ involvement in physician-
pharmacist review teams was performed in only one acute hospital. However, all the 
six restructured, acute hospitals in Singapore are managed in a similar manner and the 
results from one hospital should be able to be extrapolated to another with minor 
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variations. Also, due to severe manpower shortage on the side of the hospital, the 
study could only be run for 4 months and only in the medical discipline. Nonetheless, 
the medical discipline was chosen because of the high turn-over rate of patients and 
also based on previous experience, patients in this discipline are exposed to the 
highest risk of drug related problems due to the large number of medications they are 
on to manage their conditions. 
 
 Due to limited time, after the development of ABACUS, the final version of 
the new algorithm, only retrospective data were used for testing the new assessment 
system. There was no opportunity to use newly collected ADR reports or reports 
emerging from clinical trials to test ABACUS. 
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8.4 Recommendations for future studies 
 After having established the cost-effectiveness of having a pharmacist to 
perform pharmaceutical care role on a regular basis, it will be interesting to follow on 
with a study to verify the impact of such clinical pharmacy services on the health-
related quality of life (HRQoL) of the in-patients. The researchers postulate that there 
will be a positive impact on the HRQoL of the patients but a future study with proper 
results will provide auxiliary information to convince the hospital administrators that 
clinical pharmacy services are of great importance and should be considered seriously. 
  
 The newly developed ABACUS should be used in clinical trials, prospectively 
collected spontaneous ADR reports and also on targeted drugs, where risk 
assessments are to be established, to validate the consistency and ability of this 
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